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MW Molecular weight 
N Number of subjects 
NA Not reported 
NEB Nebulizer 
NR Not applicable 
P/C ratio Peripheral-to-central deposition ratio 
PET Positron Emission Tomography 
PK Pharmacokinetic 
pMDI Pressurized metered dose inhaler 
SD Standard Deviation 
SE Standard Error 
SLC Solute like-carrier transporter 
SPECT Single Photon Emission Computed Tomography  
Tdose Time required for zero-order/constant rate administration 
tlast Last sampling time point 
Tmax Time at peak plasma concentration 
VLLF Lung lining fluid volume 
VC Apparent volume of distribution of the central 
compartment 
vs. versus 
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There has been a desire to accurately interpret the inhaled pharmacokinetic (PK) 
profiles of drugs in humans to aid successful inhaled drug and product developments. 
However, challenges are layered, as 1) the drug dose delivered to the lung (DTL) from 
inhalers is a portion of the formulated dose but rarely determined; 2) lung delivery and 
regional deposition differ, depending on drug, formulation and inhaler; 3) drugs are not 
 
 
 
 
only absorbed from the lung but may also be from the gastrointestinal (GI) tract; and 4) in 
addition to absorption into the systemic circulation, multiple non-absorptive processes 
also eliminate drugs from the lung, such as mucociliary clearance, metabolism, 
phagocytosis and tissue binding. Hence, this thesis project aims to develop new lung 
disposition model-based analyses to derive the meaningful kinetic descriptors for lung 
disposition from inhaled PK profiles in humans. 
Two approaches, curve fitting- and moment-based approaches, were developed. 
Both approaches modeled the kinetics of lung disposition rate-controlled by absorption 
(ka) and non-absorptive loss (knal), assuming no contribution of GI absorption. An 
exhaustive literature review found necessary data sets for three drugs, tobramycin, 
calcitonin and ciprofloxacin. In the curve fitting-based approach, each inhaled PK profile 
was fitted to the lung disposition model, while the DTL was obtained from corresponding 
-scintigraphic lung deposition and the kinetic parameters of systemic disposition were 
fixed by separate intravenous PK profile model analysis. In the moment analysis-based 
approach, the mean lung residence times (MLRT) and the DTL-based bioavailability (FL) 
were estimated and used to determine the ka and knal values in the lung disposition model, 
given FL = MLRTka = ka/(ka+knal).  
The ka and knal values were successfully derived for all the three drugs delivered 
by dry powder inhalers (DPIs) and/or nebulizers (NEB) through both approaches. Their 
“goodness-of-fit” was reasonably satisfactory. The ka values appeared to be primarily 
described by partition-based diffusion affected by the three hydrophilic drug’s molecular 
weight. In contrast, the knal values differed, yet appeared to become plausible, with a 
notion of additional non-absorptive confoundedness due to lung tissue binding 
 
 
 
 
(tobramycin) and metabolism (calcitonin), in addition to mucociliary clearance. The ka and 
knal values derived by the two approaches were comparable in majority of the cases. 
The success of these PK modeling analyses enabled further attempts to identify 
most influential attributes by simulation. The systemic PK and lung exposure profiles were 
predicted by simulation upon ±20 % changes in each of the DTL, ka and knal values to 
examine changes in the systemic PK metrics (Cmax, AUC and Tmax) and local lung 
exposure metrics (AUClung and LRT0.5). For all three drugs, the Cmax and AUC changes 
were identical to changes in the DTL without changing the Tmax. In contrast, impacts of 
the ka and knal changes differed between drugs, depending on the relative contribution of 
the rate constant to their sum (ka+knal). It appeared that the major contributor of the sum 
(ka+knal) was that rate-controlling the kinetics of lung disposition. 
In conclusion, this thesis project has successfully proposed two new approaches 
of curve fitting and moment-based analysis by accurately deriving the kinetic descriptors 
of lung disposition (ka and knal) for three drugs from the inhaled PK profiles in humans. 
Their applications were extended to predict likely changes in the systemic PK and local 
lung exposure metrics by simulation. While attempts should continue with more drugs, 
these approaches are believed to be useful in identifying critical attributes to determine 
the lung disposition kinetics and thus predicting the lung kinetic behavior and systemic 
PK profiles of new drug entities in humans. 
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CHAPTER 1 
INTRODUCTION 
 
 
 
1.1  Inhaled drug delivery  
Inhaled drug delivery utilizes the lung as the route of administration primarily for 
treating local lung diseases such as asthma, chronic obstructive pulmonary disease 
(COPD) and lung infection (Labiris & Dolovich 2003; Patil & Sarasija 2012). It is also used 
to deliver drugs to treat systemic diseases like insulin for diabetes mellitus and nicotine 
for smoking cessation, while being tested in clinical trials for treating migraine (Patil & 
Sarasija 2012; Tfelt-Hansen et al. 2000). Regardless of use for local or systemic disease 
treatments, an optimal amount of drug is required to reach the lung by passing through 
the oropharyngeal cavity to produce the therapeutic responses following inhalation 
(Labiris & Dolovich 2003). This is in contrast to intravenous injection and oral 
administration, in which the entire drug dosage is directly injected into the systemic 
circulation via needles and taken by the mouth to be swallowed, respectively (Verma et 
al. 2010). While intravenous injection is capable of producing the fastest onset of action 
in less than 1 min, this route has several disadvantages, which includes a greater risk of 
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irreversible adverse effects due to higher systemic concentrations, a higher risk of 
embolism, and most critically, pain with needles (Verma et al. 2010). In this context, 
inhaled route is needle- and pain-free, and can produce the therapeutic responses as fast 
as injection for certain drug molecules, exerting the onset of action in 2-3 min. It is clear 
that this pharmacologic rapidity is much shorter than 30-90 min required for oral 
administration (Verma et al. 2010). 
Unlike intravenous injection and oral administration, however, inhaled drug 
delivery requires an appropriate choice and use of inhaler devices for successful local or 
systemic therapies (Patil & Sarasija 2012). Most commonly used inhaler devices are 
pressurized metered dose inhalers (pMDI), nebulizers (NEB) and dry powder inhalers 
(DPI). Each inhaler device requires a patient’s inspiratory effort that potentially causes 
variability as to fractions of the formulation dose to reach the lung by inhalation (Ibrahim 
et al. 2015). In this regard, training has been shown to be essential not only for proper 
use by patients in therapy but also for reproducible delivery among subjects in clinical 
pharmacokinetic or bioequivalence studies (Ibrahim et al. 2015). 
pMDIs are most commonly used for delivering drug aerosols in the treatments of 
asthma and COPD. pMDI is composed of a canister, a metering valve, an actuator and a 
mouth piece (Ibrahim et al. 2015). The canisters are made of inert materials such as 
plastic, stainless steel, glass and aluminum to hold a high pressure inside to maintain 
propellant gas in a liquid state (Newhouse 1991). pMDIs generate aerosol drug doses 
from the metering valve by actuation accurately and reproducibly, so that their dose 
emission is not influenced by inspiratory force or maneuver of patients (Newhouse 1991). 
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NEBs are inhaler devices suitable for use in pediatric, ventilated or unconscious 
patients because aerosol delivery does not require actuations and patients’ inspiratory 
coordination (Ibrahim et al. 2015). Two types of NEBs, jet and ultrasonic NEBs, are 
currently in use, depending on the type of force generating drug aerosol from solutions. 
NEBs are bulky, cumbersome inhaler devices, while allowing delivery of large aerosol 
doses; however, electric power and long inhalation time are required (Newhouse 1991).  
Unlike NEBs, DPIs are portable devices and require little coordination between 
patient inspiration and device actuation. Since DPIs formulate and deliver drugs in a dry 
powder, greater chemical stability can be achieved. However, the DPI performance 
enabling optimal aerosol generation and delivery to the lungs in patients is highly 
dependent on drug, formulation and inhaler device (Ibrahim et al. 2015). DPIs employ 
external forces like airflow shear or particle-particle and particle-device impaction to 
deaggregate and aerosolize the powder drugs. The type of such external forces depends 
on the design of DPIs. For example, Diskus, Clickhaler and Multihaler employ airflow 
shear, whereas Turbuhaler and Spinhaler rely on particle-particle and particle-device 
impaction for drug aerosol generation. Besides, a fair balance of inhaler resistance and 
airflow velocity is critical for the best DPI performance. For instance, a higher flow rate 
increases generation of aerosols suitable for deposition in the upper respiratory tract 
(Ibrahim et al. 2015). 
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1.2  Lung deposition and disposition complexities  
While inhalation therapy is intended by direct delivery of drugs to the lungs, drug 
mass delivered to the lung, regional (peripheral vs. central) lung deposition, drug mass 
deposited in the ex-lungs, e.g., oropharynx, and drug mass swallowed to the 
gastrointestinal (GI) tract, are all dependent on choice and use of inhaler device (pMDI, 
NEB or DPI) in addition to drug and formulation. The GI drug absorption and the liver 
metabolism determine how much of the swallowed drugs eventually contribute to the 
systemic drug levels (Figure 1.1). 
 
 
Figure 1.1 shows the fate of drugs after inhalation. When a patient inhales a dose 
formulated in an inhaler, only a fraction is emitted, while significant fractions remain in the 
Figure 1.1 The fate of inhaled drugs after inhalation, modified from Hochhaus (2007). 
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inhaler. Out of the emitted drug dose, some fractions are trapped in the oropharynx or 
exhaled by the patient. The fraction deposited in the lung can be subjected to mucociliary 
clearance if its rate is faster than that of dissolution (in case of dry powder aerosol) and 
cellular uptake for local pulmonary effects or absorption into the systemic circulation for 
systemic effects. The fraction deposited in the oropharynx is swallowed into the GI tract. 
Depending on its GI absorption and liver metabolism, the drug could reach the systemic 
circulation. Hence, the fate of the drug after inhalation depends on the doses deposited 
not only in the lung but also in the oropharynx, the kinetics of dissolution and absorption 
in the lung and, GI absorption and liver metabolism (Hochhaus 2007). 
As described above, regional (peripheral vs. central) deposition within the lung is 
also affected by drug, formulation and device characteristics, as well as patient factors, 
such as airway geometry, inspiratory profile, breath holding, and correct inhaler use. 
However, there are currently no established quantitative understanding between regional 
drug deposition in the lung and subsequent kinetics of lung absorption and clearance. 
Hence, in addition to the complexity due to inhaler delivery efficiency and patient factors, 
this issue of regional lung deposition needs to be taken into account for interpretation of 
the PK profile for inhaled drugs. However, such attempts remain theoretical to date, as 
described below.  
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Upon deposition in the lung as a dry powder aerosol, the drug particles must first 
be dissolved in the lung lining fluid (LLF) that covers the lung epithelia, and then taken by 
the lung cells and/or absorbed into the systemic circulation. Drug dissolution in the LLF 
depends on the drug’s solubility as well as the LLF volume available for dissolution. Given 
the lung region-dependent LLF composition, volume and depth, dissolution of inhaled 
drugs may be different in different lung regions; however, to date, such knowledge has 
not been established (Olsson et al. 2011).  
Figure 1.2 Fate of inhaled drugs following deposition in the lung: (1) Deposition onto 
and dissolution into the lung lining fluid (LLF); (2) Absorption across the pulmonary 
epithelium; (3) Phagocytic and mucociliary clearance of the undissolved particles; (4) 
Local pulmonary metabolism; and (5) Lung tissue binding. The figure is modified from 
Ruge et al. (2013). 
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In general, lipophilic drugs are absorbed across the lung epithelia via passive 
diffusion, whereas hydrophilic drugs pass through tight junctions between epithelial cells 
(via paracellular route). In addition, drugs can be actively absorbed via solute-like carrier 
(SLC) transporter processes as well as endo/trans-cytosis. Therefore, lung absorption 
may be comprised of such multiple processes that simultaneously occur at different rates. 
Such lung absorption rates may also vary in different lung regions upon deposition. For 
instance, drug absorption in the peripheral lung is likely faster due to higher rate of 
perfusion, a greater surface area (100 m2) and a thin diffusion epithelial barrier (Borghardt 
et al. 2015). 
In addition to dissolution and absorption, there are other kinetically competing 
processes, which may contribute to clearance of inhaled drugs from the lung. These 
include mucociliary clearance, lung metabolism, phagocytic clearance and lung tissue 
binding (Labiris & Dolovich 2003; Patton & Byron 2007). When drug particles deposited 
in the lung remain insoluble, such particles are trapped in the gel layer of the LLF, cleared 
toward the pharynx by an upward mucus movement by cilia beating, and eventually 
swallowed to the GI tract. Both the total drug mass deposited in the lung and regional 
lung deposition may be different among subjects. Especially in patients with asthma and 
COPD, their smaller airway cross-sectional areas cause more impaction in the central 
parts of the lung. This results in greater mucociliary clearance loss due to faster cilia 
movement in the central lung, compared to the peripheral lung, thereby possibly 
explaining a reduced systemic exposure in patients seen for some corticosteroids (Olsson 
et al. 2011). Thus, depending on the regional lung deposition as well as lung disease 
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state, mucociliary clearance may enable removal of the drugs from the lung before 
absorption or local pharmacologic effects. 
All the drug-metabolizing enzymes found in the liver are also found throughout the 
conducting airways and lung alveoli, yet to a lesser extent. Cytochrome P450 (CYP450) 
enzymes, flavin-containing monooxygenases (FMO), monoamine oxidase (MAO), 
aldehyde dehydrogenase, NADPH-CYP450 reductase are all found in the lungs. Protein 
and peptide drugs are highly degraded by proteases that are found in the lung epithelia, 
alveolar macrophages and other inflammatory cells like neutrophils (Labiris & Dolovich 
2003). When the drug is susceptible to degradation by such lung’s metabolizing enzymes, 
it may contribute as non-absorptive clearance of the drug from the lung. 
Drug particles deposited in the alveolar region are cleared by macrophages when 
the drugs are insoluble or slowly dissolved and absorbed to the systemic circulation. 
These alveolar macrophages phagocytose such drug particles and then translocate them 
into the ciliated airways for mucociliary clearance. The alveolar macrophages are also 
sources for lung proteases that metabolically degrade proteins and peptides, and the 
protease expression may differ, depending on disease states of the lungs, but is largely 
unknown (Labiris & Dolovich 2003). 
Lipophilic or hydrophilic molecules that carry positive charge under physiological 
conditions, such as pentamidine, verapamil and tobramycin, are mostly basic amines, 
and thus may bind favorably to the lung tissue, namely via phospholipids or lysosomes 
(Patton & Byron 2007). Their lysosomal uptake is caused by trapping, i.e., unionized weak 
bases permeate and accumulate in the acidic interior of lysosomes, where the molecules 
get protonated and thus cannot diffuse back into the cytosol. The uptake of such basic 
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amines into the lysosomes depends on the lysosomal pH (Boer 2003). Thus, lung tissue 
binding may lead to slowing down of lung’s mucociliary clearance and in turn possibly 
increase the duration of local effects.  
 
1.3  Methods to determine total and regional drug lung deposition 
As described previously, only a fraction of the drug dose formulated in an inhaler 
device is deposited in the lung after inhalation. Additionally, the regional lung deposition 
varies, depending on the drug, formulation and inhaler, along with a variability caused by 
patient factors. The drug mass deposited in the lung and regional lung deposition is 
therefore of interest of kinetically analyze the systemic PK profile data of inhaled drugs.  
In vitro impactor-based testing methods classify inhaler device-generated aerosol 
particles, and “respirable” particles are generally defined as those with mass median 
aerodynamic diameter (MMAD) between 1 and 5 µm, i.e., “respirable fraction” or “fine 
particle fraction” (FPF). The particles larger than that size are “non-respirable” which are 
to impact on the oropharynx (after which they are swallowed and may be absorbed from 
the GI tract). The simplest apparatus to determine such “respirable” particle mass is the 
Twin Impinger, which has an angled “throat” and two collecting chambers, among which 
the drug particles reaching the second chamber are classified as “respirable” ones. In 
contrast, the Anderson cascade impactor (ACI) allows more detailed collection of inhaler 
device-generated aerosol particles into eight size fractionations that precede the right-
angled USP induction port. Generally, while reproducible FPF data are important for 
quality-control, these in vitro impactor methods possess a number of drawbacks for 
prediction of lung deposition, given that the anatomy of the human respiratory tract is 
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complex and therefore poorly represented by these collection chambers or plates 
alongside their “throat” (Snell & Ganderton 1999; Chrystyn 2001). Daley-Yates et al. 
(2014) compared in vitro fine particle mass of Rotahaler and Diskus inhalers for 
fluticasone propionate and salmeterol against the in vivo performance of both the inhalers 
and found that the in vitro results had poor sensitivity and predictability of in vivo results. 
It was observed that even though the in vitro results were comparable for both inhalers, 
the in vivo exposure metrics area under the plasma concentration vs. time curve (AUC) 
was larger and time for maximum plasma concentration (Tmax) was shorter for Rotahaler 
compared to Diskus. This was noted to be probably due to a larger dose delivered to lung 
and a greater peripheral deposition from Rotahaler due to a larger dose emission duration 
of 3 seconds compared to a mere 0.3 seconds from Diskus. A shorter dose emission 
duration may cause greater oropharyngeal and central lung deposition due to impaction 
with walls of these regions. However, since in vitro techniques do not closely mimic the 
complexity of the human oropharyngeal and respiratory anatomy, they were not found to 
be good predictors of in vivo performance of these inhalers.  
Conventional pharmacokinetic (PK) analysis is challenging for inhaled drugs, 
because the systemic (plasma or serum) drug levels may be confounded by GI absorption 
of the swallowed fraction from the oropharyngeal deposition, in addition to lung 
absorption. Accordingly, co-administration of activated charcoal can be used to block GI 
absorption to reflect the systemic levels exclusively due to lung absorption. Note however 
that this becomes important only when the drug has considerable oral bioavailability. 
Some studies used the drug mass in urine collected in the first 30 min of inhaled 
administration as a quantitative measure of lung deposition and absorption. Even so, the 
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rate of absorption across the lung is variable and affected by depth of inspiration and 
breath-holding, as well as dissolution in the LLF following regional lung deposition. 
Therefore, such approaches best reflect whole lung drug deposition, while giving no 
information on lung region-dependent deposition and disposition (Chrystyn 2001). 
Imaging techniques like the two dimensional -scintigraphy involve radiolabeling of 
inhaled drugs in formulations using a -emitting radioisotope like 99mtechnetium. The 
whole lung, oropharynx and stomach as well as the inhaler device and the exhalation filter 
are imaged using a -camera. The method also allows differentiation of “central” and 
“peripheral” lungs, thereby estimating not only total lung deposition but also regional lung 
deposition. While three-dimensional imaging methods like single photon emission 
computed tomography (SPECT) and positron emission tomography (PET) are also 
available, they are much more expensive, time consuming, and require highly skilled and 
experienced personnel to perform the imaging. As a result, two dimensional 
scintigraphy has been most widely used to determine the total and regional lung 
deposition (Chrystyn 2001; Snell & Ganderton 1999). 
 
1.4 PK modeling approaches 
The total and regional deposition, aerosol drug dissolution, and absorptive and 
non-absorptive clearance processes in the lungs have made accurate understanding of 
lung disposition for inhaled drugs difficult and challenging. Successful attempts should 
derive and predict such complex kinetics of inhaled drugs by incorporating mucociliary 
clearance, absorption to the systemic circulation via the lung and the GI tract, and 
 
 
12 
 
dissolution in the LLF (Weber & Hochhaus 2013; Sakagami 2014). A distinction can be 
made in the model between central vs. peripheral lung depending on the goal of the 
modeling approach. While making this distinction allows accounting for disposition 
complexity due to inherent physiological differences in the lung, like faster absorption from 
peripheral lung and faster mucociliary clearance rate in the central lung; incorporating this 
distinction in the model makes the model more complex and necessitates making certain 
assumptions which may not be universally applicable. For example, when using a model 
which distinguishes the lung into different compartments and using that model to fit to PK 
data from COPD patients, the assumption that mucociliary clearance is faster from central 
lung may not hold true because of the impaired mucociliary clearance in such patients. 
Development of a compartmental PK model to describe this complex lung 
disposition PK requires use of assumptions based on knowledge like different lung 
absorption rates due to physiological characteristics of the lung, parameters to describe 
different absorptive and non-absorptive routes that the drug may take after deposition, as 
well as formulation based assumptions, and therefore, a compromise between simplicity 
and realism is necessary in modeling approaches, depending on the specific goal of the 
modeling approach. (Borghardt et al. 2015) When the goal of the modeling approach is 
to understand how disposition kinetics are inhaler- and drug-dependent, it may be feasible 
to regard the lung as a single compartment in the model to simplify the model and 
decrease the number of parameters in the model that need to be derived, thereby 
preventing overparameterization of the model. An example of a complex PK model was 
published by Miller et al. (2010) which was developed with the goal to predict budesonide 
inhaled drug PK profile. It was observed that the model prediction of the Cmax and Tmax of 
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the budesonide inhaled PK profile were slightly deviated from the literature budesonide 
inhaled PK profile. This may be because the model described the lungs as a collection of 
up to five compartments (nose, extra-thoracic, thoracic, bronchiolar and alveolar). The 
lung disposition was assumed to be controlled by dissolution, absorption into pulmonary 
cells and eventually into systemic circulation, mucociliary clearance and metabolism with 
a parameter included in the model for each process; while also accounting for fractions 
of unbound drug in the mucus/surfactant layers and the pulmonary cells. In addition, the 
model also used literature values to describe human lung physiological parameters 
(surface area, thickness and volume for the mucus and cell) for each of the five lung 
compartments, pulmonary permeability and systemic PK parameters. Thus, these large 
number of parameters in the model could have overparameterized the model, causing 
some deviations in the observed budesonide PK profile and the predicted profile.  
 
Another example of the modeling approach was published by Weber and 
Hochhaus (2013) where the PK parameter estimates were derived from the literature to 
describe the systemic PK profiles of inhaled drugs. The PK parameters that were 
unavailable in the literature were assigned with assumptions for characteristics of 
absorption rate constants and pulmonary deposition patterns. The authors also assumed 
the fraction of the dose deposited in the mouth-throat to be swallowed and absorbed from 
the GI tract to contribute to the systemic drug levels, when appropriate.  Notably, the drug 
dose deposited in the lung was differentiated into two kinetically different absorption, by 
modeling different rates of absorption from two lung compartments, the central and 
peripheral lungs. In addition, the rate estimates for mucociliary clearance and dissolution 
were obtained from the literature and included in the PK model. Simulations were 
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performed with this PK model, which were found to be well compared with the PK results 
of four clinical studies. Thus, by comparing this model to the previous example published 
by Miller et al., it may be speculated that a simpler model with less number of parameters 
allowed prediction of PK profiles more consistent with the literature PK profiles. However, 
the impactor data was used as the total and regional lung deposited doses, which would 
require caution, because as described previously, such in vitro data may not accurately 
represent drug dose to lung due to poor sensitivity and predictive capability of in vitro data 
to in vivo performance. 
 Subsequently, Sakagami (2014) employed another kinetic model which 
incorporated a fraction of the dose deposited in the lung as well as regional lung 
deposition in the central and peripheral lungs, in addition to dissolution rate-controlled 
lung absorption and mucociliary clearance from both the central and peripheral lung to 
analyze clinical PK profiles from the literature for inhaled fluticasone propionate and 
fluticasone furoate. In the model, the systemic PK parameters and mucociliary clearance 
kinetics were fixed at their literature values. The model fitting was found to be successful 
in explaining and predicting the PK profiles for both inhaled drugs. However, the total and 
regional lung deposition fractions were derived from impactor data, which may not 
accurately predict in vivo deposition. This model distinguished the lung into two 
compartments, while assuming that the dissolution controlled-rate of absorption of 
fluticasone was unaltered in these two lung regions. Thus it remains to be seen how the 
prediction accuracy of the model would change in this case by including the lung as a 
single compartment in the model, thereby allowing a decrease of the number of 
parameters in the model.  
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The lung disposition kinetics is complex and confounded by many variables like 
lung delivery and deposition, dissolution in the LLF, absorption and several other 
clearance processes such as mucociliary clearance, metabolism, phagocytosis and 
tissue binding. However, it is desirable to minimize this complexity using a simpler lung 
deposition and disposition-based compartmental PK model which allows a compromise 
between simplicity and realism, so that accurate derivation and prediction of key 
parameters determining the inhaled PK profiles may become feasible.  In pursuit of this 
goal, this thesis research describes use of a simpler lung deposition and disposition PK 
model to derive the lung disposition kinetic descriptors of three drug molecules using 
curve fitting- and moment analysis-based approaches. Simulation was then performed to 
assess the effects of changes in lung delivery and disposition parameters on the systemic 
PK and local lung exposure profiles. 
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CHAPTER 2 
HYPOTHESIS AND SPECIFIC AIMS 
 
 
 
This thesis project aims to apply the lung disposition model-based analysis to the 
inhaled pharmacokinetic (PK) profile data for three drugs in humans to derive accurate 
kinetic descriptors (rate constants) for lung disposition with negligible GI absorption. It is 
hypothesized that their lung disposition kinetics can be described with absorption (ka) and 
non-absorptive loss (knal), derived from the inhaled PK profiles and corresponding -
scintigraphic lung deposition data by using curve fitting-based and moment-based 
approaches. By so doing, such kinetic descriptors of lung disposition can be identified 
and discussed as drug-, inhaler- and lung deposition-dependent values. Moreover, 
inhaled PK profile prediction by simulation enables identification of the impact of 
change/difference/variance of each attribute. The project is designed to pursue the 
following five specific aims:     
1. Identify drugs with available necessary data sets (i.e., inhaled PK profiles and 
corresponding -scintigraphic lung deposition data alongside intravenous PK profiles) 
by performing an exhaustive literature review 
2. Develop a lung deposition and disposition-based compartment model for inhaled PK 
profile analysis using curve fitting-based and moment-based approaches  
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3. Derive the kinetic descriptors of lung absorption and non-absorptive loss (ka and knal, 
respectively) for three drugs through curve fitting-based approach 
4. Derive the kinetic descriptors of lung absorption and non-absorptive loss (ka and knal, 
respectively) for three drugs through moment-based approach 
5. Predict changes in the inhaled PK profiles and their parameter metrics in response to 
±20 % change/difference/variance of each attribute by simulation 
In Chapter 3, upon literature selection of three drugs, i.e., tobramycin, calcitonin 
and ciprofloxacin, their inhaled PK profiles will be analyzed using curve fitting-based 
approach to derive drug-, inhaler- and/or lung deposition-dependent ka and knal values. In 
Chapter 4, the identical inhaled PK and lung deposition data sets will be analyzed using 
moment-based approach to derive and compare the ka and knal values. In Chapter 5, 
inhaled PK and lung exposure profiles will be predicted by simulation in response to ±20 
% change/difference/variance of each attribute from the reference standard condition. 
Finally, Chapter 6 will summarize all the findings in this thesis project and provide overall 
conclusions.  
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CHAPTER 3 
LUNG DISPOSITION KINETIC ANALYSIS VIA CURVE FITTING APPROACH 
 
 
 
3.1  Introduction 
As described in Chapter 1, lung disposition kinetics of inhaled drugs is complex 
and thus its accurate understanding is challenging. 1) Only a portion of the formulated 
drugs is deposited in the lung, which is rarely determined; 2) lung-deposited drugs are 
absorbed from the lung, but absorption may also occur, when drugs are swallowed and 
reach the gastrointestinal (GI) tract; and 3) lung delivery and regional deposition depend 
on formulation and inhaler, which may cause different pharmacokinetic (PK) profiles 
(Hochhaus 2007). Even so, more accurate understanding of the inhaler- and lung 
deposition-dependent kinetic behavior is desired to aid successful inhaled drug and 
product development for local and systemic use in patients.  
Nonlinear regression curve fitting can be a powerful approach to derive kinetic 
descriptors for such multi-complex deposition and disposition kinetics in the lungs for 
inhaled drugs from the PK profile data. In this chapter, the literature was searched and 
three drugs tested for inhalation, tobramycin, calcitonin and ciprofloxacin, were chosen, 
based on availability of all necessary data sets: a) dose deposited in the lung (DTL) by -
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scintigraphy; b) intravenous injection/infusion (IV) profile data; and c) inhaled PK profile 
data. Hence, the lung deposition and disposition were kinetically modeled along with the 
systemic disposition and used for curve fitting the PK profiles to derive the lung disposition 
kinetic descriptors, the rate constants of absorption (ka) and non-absorptive loss (knal) 
using Scientist® 3.0 (MicroMath, Saint Louis, MO). 
 
3.2  Methods 
3.2.1  Literature data collection 
An exhaustive literature search was conducted in PubMed and Google Scholar to 
identify the following data sets for drugs in healthy subjects for use in this curve fitting-
based lung disposition kinetic analysis: 1) PK profile and -scintigraphy lung deposition 
data following inhalation with the same inhaler device; 2) lack of GI absorption and 3) PK 
profile data following IV injection/infusion. The search terms used in PubMed and Google 
Scholar were “inhalation PK profile with lung deposition by -scintigraphy in healthy 
volunteers” for inhaled PK profiles alongside corresponding inhaler’s dose delivered to 
lung. Following identification of drug molecules with such available data sets for inhaled 
PK, the search term “IV PK profile healthy volunteers” for the corresponding drug 
molecule was used to identify IV PK profiles. Following identification of all necessary data 
sets, the study design and details, e.g., the number and demographics of healthy 
subjects, dose and plasma/serum concentration, sampling time interval and duration, 
drug assay method and validation, were also carefully inspected to be consistent or 
comparable across the studies. As a result, tobramycin, calcitonin and ciprofloxacin were 
chosen for use in this study, and their mean plasma/serum concentration vs. time profile 
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data for IV and inhaled administration were extracted using GetData Graph Digitizer, a 
program to digitize graphs and plots (http://getdatagraphdigitizer.com). Notably, these 
three drugs differ with respect to their physicochemical properties and the absence 
(tobramycin and calcitonin) or presence (ciprofloxacin) of GI absorption, as shown in 
Table 3.1.  
 
Drug Tobramycin Calcitonin Ciprofloxacin 
MW (Da) 468 3,432 331 
Log KD -10 -33 -2 
Aqueous solubility 
(mg/ml) 
>50 1 0.08 
Oral bioavailability 
(%) 
<1 due to low 
permeability 
<1 due to 
proteolytic 
degradation 
70 
Inhaler device DPI, NEB DPI, NEB DPI 
KD: Distribution coefficient, DPI: Dry powder inhaler, NEB: Nebulizer 
 
3.2.2  Estimation of systemic PK parameters 
Systemic PK parameters were estimated from the IV PK profile data first by the 
method of residuals, followed by nonlinear regression curve fitting using Scientist® 3.0 
(MicroMath, Saint Louis, MO). The parameter values derived by method of residuals were 
used as initial estimates to derive the best estimates using curve fitting. Method of 
residuals employs linear regression of the α- and β-phases of the PK profiles which allows 
derivation of a single value as the parameter estimate. However, curve fitting employs 
nonlinear regression for curve fitting which derives the “best” estimate by reaching the 
global minimum value as the parameter estimate. Thus, nonlinear regression curve fitting 
was employed to more accurately derive PK parameter estimates. The one- or two-
Table 3.1. Physicochemical properties and absence/presence of GI absorption of 
tobramycin, calcitonin and ciprofloxacin. 
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compartment open body model shown in Figure 3.1 or 3.2, respectively, was used 
depending on the mono- or bi-exponential decline in the PK profiles. The PK profiles that 
follow the one-compartment model (Figure 3.1) were generally described by: 
dMC/dt = k0 - k10 * MC                                     Equation 3.1 
where MC is the drug mass in the central compartment; k0 is the zero-order infusion rate 
for IV infusion during the infusion period and otherwise, 0 for IV bolus injection or IV 
infusion after the infusion period; and k10 is the first-order elimination rate constant from 
the central compartment. In contrast, the PK profiles that follow the two-compartment 
model (Figure 3.2) were described by: 
dMC/dt = k0 + k21 * MP - (k12+k10) * MC                                   Equation 3.2 
where MP is the drug mass in the peripheral compartment; k12 and k21: the first-order rate 
constants for transfer from the central to the peripheral compartment and from the 
peripheral to the central compartment, respectively; and k0 is as described previously. 
The IV PK profiles were first analyzed using the method of residuals as described 
in Gibaldi & Perrier (1982) to estimate the rate constant and VC values for use as the 
initial estimates in the subsequent curve fitting. With these initial estimates, the nonlinear 
regression curve fitting was performed using Scientist to more accurately derive each of 
the rate constant and VC values. The goodness-of-fit of the curve fitting was assessed 
with the 95% confidence intervals (CI) for the derived estimates, Scientist-derived 
coefficient of determination (COD) and model selection criterion (MSC), and visual 
inspection of residuals in the PK profiles. 
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k10 
Central  
compartment 
VC 
IV bolus or infusion 
Figure 3.1. One-compartment open body model: k10; first-order rate constant for 
elimination; and VC: apparent volume of distribution of the central compartment. 
 
MC 
k12 
k21 
k10 
Central  
compartment 
Peripheral  
compartment 
VC 
IV bolus or infusion  
Figure 3.2 Two-compartment open body model: k10, k12 and k21: the first-order rate 
constants for elimination from the central compartment, transfer from the central to the 
peripheral compartment, and transfer from the peripheral to the central compartment, 
respectively; and VC: apparent volume of distribution of the central compartment. 
MC MP 
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3.2.3  Curve fitting-based estimation of lung disposition kinetic parameters 
Each of the inhaled PK profile data was then curve-fitted to the lung deposition and 
disposition model shown in Figure 3.3. Note that the systemic disposition model was 
either of the one or two-compartment model shown in Figure 3.1 or 3.2, respectively. The 
kinetics of lung disposition were assumed to be controlled with the first-order rate 
constants of absorption (ka) and non-absorptive loss (knal), which was described by: 
dML/dt = -(ka+knal) * ML                                                    Equation 3.3 
Upon inhaled administration (t=0), lung deposition, ML,0 was equaled to DTL. Hence, the 
systemic compartment disposition was kinetically controlled not only by distribution and 
elimination but also by the input rate of ka*ML, i.e., lung absorption. 
In this lung disposition PK model, the DTL was obtained from the -scintigraphy 
data for each drug dosed with the inhaler in the subjects, consistent with those used to 
obtain the inhaled PK profile data. The systemic disposition PK parameters were fixed at 
the values obtained by curve fitting the IV PK profile data described above in 3.2.2. Hence, 
all the parameters except ka and knal were fixed, and the inhaled PK profile data were 
fitted to the model using Scientist to derive the best parameter estimates for ka and knal. 
The goodness-of-fit of the curve-fitting was assessed with the 95% CIs for the derived 
best parameter estimates, Scientist-derived COD and MSC, and visual inspection of 
residuals in the PK profiles. 
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ka 
knal 
Systemic disposition 
Elimination 
Lung 
DTL 
Figure 3.3 The lung deposition and disposition model incorporating absorption and 
non-absorptive loss, along with the systemic elimination. The lung receives dose-to-
the lung (DTL) upon inhaled administration. Lung’s absorption and non-absorptive loss 
are kinetically described with the first-order rate constants, ka and knal, respectively. 
The systemic disposition follows either one- or two-compartment model described in 
Figure 3.1 and 3.2, respectively. Hence, the systemic disposition kinetics were 
controlled not only by elimination and distribution but also by lung absorption as an 
input function. 
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3.3  Results and Discussion 
3.3.1   Literature data collection 
 By employing the search terms “inhalation PK profile with lung deposition by -
scintigraphy in healthy volunteers” in PubMed and Google Scholar, research papers were 
identified for albuterol, budesonide, calcitonin, ciprofloxacin and tobramycin. After a 
thorough review of the five identified research papers, it was observed that inhaled PK 
study of albuterol (Hirst et al. 2002) reported only the -scintigraphy lung dose without the 
corresponding inhaled PK profile in healthy volunteers. In case of budesonide, the 
identified inhaled PK study (Thorsson et al. 1994) reported only the inhaled PK profile 
without GI absorption without the corresponding -scintigraph lung dose. On the contrary, 
in case of tobramycin, calcitonin and ciprofloxacin, both necessary data sets of inhaled 
PK profile without GI absorption and corresponding -scintigraphy lung deposition data 
following inhalation with the same inhaler device were identified. Therefore, intravenous 
injection/infusion (IV) PK profile literature data search was conducted only for tobramycin, 
calcitonin and ciprofloxacin and albuterol and budesonide were eliminated from the list of 
drug molecules eligible for this project on account of unavailability of all necessary data 
sets.  
 
3.3.2  Tobramycin 
The IV PK profile data were taken from Pleasants et al. (1988) which employed 
0.5 h infusion at a dose of 1.5 mg/kg. The -scintigraphic DTL and inhaled PK data were 
taken from Newhouse et al. (2003), obtained following 0.25 h inhaled administration of 
spray-dried powders from Turbospin DPI (DPI) and solution aerosols from PARI LC Plus 
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Nebulizer (NEB). The study design and details are summarized in Table 3.2, which was 
considered comparable. The IV and inhaled PK profiles are shown in Figure 3.4 and 3.5, 
respectively, while the -scintigraphic data are shown in Table 3.3. Given the linear PK 
assumption of the lung deposition and disposition PK model, literature IV and inhaled PK 
data were assessed for dose proportionality. Literature reported IV dose (Pleasants et al.) 
and DTL (Newhouse et al.) for DPI and NEB were assessed for linearity with the 
corresponding literature reported area under the serum concentration vs. time curve 
(AUC) and it was observed that AUC showed dose linearity. Hence it was assumed that 
tobramycin followed linear PK at the reported IV dose and DTL for both inhalers. 
 
Literature  IV PK  
Pleasants et al. 
DTL and inhaled PK  
Newhouse et al. 
DPI NEB 
Subject (N) 12 12 
Gender (M/F) 12/0 10/4  
Race NR NR  
Age (years)* 26 ± 3 34 ± 8  
Weight (kg)* 78.8 ± 11.4 NR  
    
Formulation dose  1.5 mg/kg 80 mg 300 mg 
Infusion time (h) 0.5 NA NA 
    
Sampling points (h) 0.17, 0.33, 0.50, 0.67, 
0.83, 1.00, 1.33, 1.50, 
1.67, 2.00, 2.50, 3.00, 
4.00, 6.00, 8.00 
0, 0.25, 0.50, 1.00, 1.50, 2.00, 3.00, 
4.00, 6.00, 8.00 
Assay method Fluorescence 
polarization 
immunoassay 
Fluorescence polarization 
immunoassay 
LLOQa (mg/L) 0.18 0.05 
*Mean ± SD; aLower limit of quantitation; NR: Not reported; and NA: Not applicable 
Table 3.2 Study design and drug assay method for the studies used in the curve fitting-
based lung disposition kinetic analysis for tobramycin. 
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Figure 3.4 Mean serum tobramycin concentration vs. time following 0.5 h IV infusion 
at a dose of 1.5 mg/kg. Data were taken from Pleasants et al., (1988). 
Figure 3.5 Mean (± SD) serum tobramycin concentration vs. time following inhaled DPI 
and NEB administration. Data were taken from Newhouse et al. (2003). 
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Device DPI NEB 
DPI capsule 13.3 ± 4.2 NA 
Turbospin inhaler 8.4 ± 1.0 NA 
Nebulizer cup NA 55.7 ± 5.6 
Nebulizer mouthpiece and 
T-piece 
NA 4.9 ± 2.2 
Exhalation filter 0.20 ± 0.10 26.4 ± 3.2 
Emitted dose 78.3 ± 10.3 39.4 ± 5.1 
Oropharynx, esophagus 
and stomach 
43.6 ± 8.6 8.2 ± 3.6 
DTL  34.3 ± 5.8 5.0 ± 2.0 
P/C ratio 1.6 ± 0.4 1.5 ± 0.4 
 Data: Mean ± SD; NA: Not applicable; P/C ratio: Peripheral-to-central deposition ratio 
It should be noted that DPI and NEB employed substantially different doses (80 
and 300 mg, respectively; Table 3.2), as well as differences in % emitted dose (78.3 and 
39.4%; Table 3.3) and % DTL (34.3 and 5%; Table 3.3) were reported. As a result, the 
DTL calculated from the formulation dose and % DTL were 27.4 mg for DPI and 15.0 mg 
for NEB. That is, the DTL for DPI was almost twice of that for NEB in this study. 
With the IV profile data shown in Figure 3.4, the initial estimates for the systemic 
two-compartment model disposition parameters obtained by the method of residuals are 
shown in Table 3.4. Curve-fitting was then performed with Scientist, which was 
successful, given 0.99 of COD and 4.2 of MSC as well as small residuals seen in profiles, 
as shown in Figure 3.6. As a result, the best parameter estimates were derived in a more 
accurate manner, as also shown in Table 3.4. It was observed that method of residuals 
derived rate constants k10, k12 and k21 were bracketed by the 95% CI of those derived by 
curve fitting. However, method of residuals appeared to underestimate the VC, which may 
have been because method of residuals does not allow accounting for the time of infusion, 
Table 3.3 % tobramycin deposition following inhaled DPI and NEB administration, 
measured by -scintigraphy. Data were taken from Newhouse et al. (2003). 
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which was incorporated in curve fitting based estimation of the parameters, thereby 
allowing an accurate estimation of the parameters. 
 
Systemic PK parameter Initial estimate Best estimate 
k10 (h-1) 
(95% CI) 
0.63 0.53 
(0.41, 0.65) 
k12 (h-1) 
(95% CI) 
0.50 0.36 
(0.14, 0.58) 
k21 (h-1) 
(95% CI) 
0.83 0.69 
(0.09, 1.48) 
VC (L) 
(95% CI) 
8.27 11.4 
(10.5, 12.3) 
 
 
 
 
The inhaled PK profile data for DPI and NEB shown in Figure 3.5 were each curve-
fitted to the kinetic model shown in Figure 3.3. The DTL was fixed at 27.4 mg for DPI and 
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Figure 3.6 The model-predicted profile of the serum concentration of tobramycin vs. 
time following IV infusion. Data were taken from Pleasants et al. The dashed line is the 
model-predicted profile generated using the best parameter estimates shown in Table 
3.4. 
Table 3.4 Values of the initial estimates obtained by the method of residuals and the 
best estimates derived by the curve fitting for the two-compartment model parameters 
of tobramycin from the IV PK profile data. 
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15.0 mg for NEB, as estimated from the -scintigraphic data (i.e., the formulation dose x 
% DTL). The systemic disposition parameters were also fixed with the values derived 
from the IV PK profile data, as shown above. While these were fixed, the lung disposition 
kinetic parameters, ka and knal, were floated in curve fitting with Scientist to be derived 
from each of the inhaled PK profiles of Newhouse et al. The derived ka and knal values 
are shown in Table 3.5, along with the goodness-of-fit parameters, COD and MSC. In 
Figure 3.7, only small deviations are shown between the data and the prediction, 
demonstrating sufficient curve-fitting, despite slightly lower MSC and COD values (Table 
3.5). The lower COD and MSC values may be because the number of data points before 
the maximum serum concentration (Cmax) after inhalation from both DPI and NEB were 
only 3, with a total of 9 data points in the sampling duration of 8 h. Such limited number 
of data points penalizes the MSC and COD values due to overparameterization of the 
model, which relies on the total number of data points as well as the data points around 
the higher concentrations available for curve fitting to derive the ka and knal values. 
 
Device ka (h-1) 
(95% CI) 
knal (h-1) 
(95% CI) 
COD*  MSC+ 
DPI 0.45 
(0.35, 0.55) 
0.08 
(0.02, 0.17) 
0.89  1.78 
NEB 0.34 
(0.28, 0.40) 
0.08 
(0.01, 0.15) 
0.92  2.15 
*Coefficient of determination; +Model selection criteria 
 
Table 3.5 The best parameter estimates for the ka and knal values of tobramycin derived 
through curve-fitting of the inhaled PK profile data reported in Newhouse et al, along 
with the Scientist-derived goodness-of-fit parameters, COD and MSC. 
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3.3.3  Calcitonin 
The IV PK profile data were taken from Buclin et al. (2002), which employed 1 h 
infusion at a dose of 10 µg. The -scintigraphic DTL and inhaled PK data were taken from 
Clark et al. (2008), obtained following inhaled administration of spray-dried powders from 
Nektar pulmonary delivery system (DPI) and 0.04 h inhalation of solution aerosols from 
Salter nebulizer (NEB). The study design and details are summarized in Table 3.6, which 
was considered comparable. The IV and inhaled PK profiles are shown in Figure 3.8 and 
3.9, respectively, while the -scintigraphic data are shown in Table 3.7. Both the IV and 
inhaled PK studies employed immunoassay based techniques to measure calcitonin 
concentrations after IV and inhaled administration. Given the issues of cross-reactivity 
based interference with immunoassay techniques, and since the inhaled PK study in 
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Figure 3.7 The model-predicted profiles of the serum concentration of tobramycin vs. 
time following inhaled DPI and NEB administration. Data were taken from Newhouse 
et al. The dashed lines are the model-predicted profiles generated using the best 
parameter estimates shown in Table 3.5.  
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Clark et al. did not comment on the specificity of the radioimmunoassay technique used 
alongside possible metabolite cross-reactivity, it was assumed that the reported plasma 
concentrations after IV and inhaled administration were accurate, until further information 
on cross-reactivity is available through literature for that specific radioimmunoassay 
technique used in Clark et al.  Given the linear PK assumption of the lung deposition and 
disposition PK model, literature IV and inhaled PK data were assessed for dose 
proportionality. Literature reported IV dose (Buclin et al.) and DTL (Clark et al.) for DPI 
and NEB were assessed for linearity with the corresponding literature reported area under 
the serum concentration vs. time curve (AUC) and it was observed that AUC showed 
dose linearity. Hence it was assumed that calcitonin followed linear PK at the reported IV 
dose and DTL for both inhalers. 
 
Literature  IV PK  
Buclin et al. 
DTL and inhaled PK  
Clark et al. 
DPI NEB 
Subject (N) 8 16 
Gender (M/F) 8/0 8/8  
Race NR NR  
Age (years) 22-37* 32+  
Weight (kg)* 65-86 NR  
    
Formulation dose 10 µg 300 µg NR 
Infusion time (h) 1 NA NA 
    
Sampling points (h) 0, 0.25, 0.50, 0.76, 1.00, 
1.50, 2.00 
0, 0.08, 0.17, 0.33, 0.5, 1, 2, 4, 6 
Assay method Chemoluminescence-
based sandwich 
immunoassay 
Radioimmunoassay 
LLOQa (pg/ml) 2.5 NR 
*Range; +Mean; aLower limit of quantitation; NR: Not reported; and NA: Not applicable 
Table 3.6 Study design and drug assay method for the studies used in the curve fitting 
-based lung disposition kinetic analysis for calcitonin. 
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Figure 3.8 Mean (± SD) plasma calcitonin concentration vs. time following 1 h IV 
infusion at a dose of 10 µg. Data were taken from Buclin et al. (2002). 
 
Figure 3.9 Mean (± SD) plasma calcitonin concentration vs. time following inhaled DPI 
and NEB administration. Data were taken from Clark et al. (2008). 
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Device DPI NEB 
DTL (µg) 52.9 ± 12.8 56.9 ± 9.00 
P/C ratio 0.8 ± 0.3 1.4 ± 0.3 
Data: Mean ± SD; P/C ratio: Peripheral-to-central deposition ratio 
It should be noted that DPI employed 300 µg of the formulation dose, while the 
dose formulated in NEB was not reported (Table 3.6).  The DTL was reported 52.9 µg for 
DPI and 56.9 µg for NEB. That is, the DTL was comparable between DPI and NEB 
administration in this study (Table 3.7). 
With the IV profile data shown in Figure 3.8, the initial estimates for the systemic 
one-compartment model disposition parameters were obtained, as shown in Table 3.8. 
Curve fitting was then performed with Scientist, yielding 0.95 of COD and 2.46 of MSC. 
As shown In Figure 3.10, small deviations were seen between the actual and model-
predicted profiles, demonstrating sufficient curve-fitting. As a result, the best parameter 
estimates were derived in a more accurate manner, as shown in Table 3.8. It was 
observed that the k10 and VC derived by method of residuals were bracketed by 95% CI 
of those derived by curve fitting, however it is believed that curve fitting allows a more 
accurate estimation of parameters because as described previously, curve fitting employs 
nonlinear regression which allows derivation of the “best” estimate while reaching the 
global minimum. 
Table 3.7 Calcitonin deposition (µg) following inhaled DPI and NEB administration, 
measured by -scintigraphy. Data were taken from Clark et al. (2008). 
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Systemic PK parameter Initial estimate Best estimate 
k10 (h-1) 
(95% CI) 
3.77 3.72 
(1.24, 6.21) 
VC (L) 
(95% CI) 
15.0 17.9 
(8.24, 27.6) 
 
 
 
 
The inhaled PK profile data for DPI and NEB shown in Figure 3.9 were each curve-
fitted to the kinetic model shown in Figure 3.3. The DTL was fixed at 52.9 µg for DPI and 
56.9 µg for NEB, as reported by -scintigraphy. The systemic disposition parameters were 
also fixed with the values derived from the IV PK profile data, as shown above. While 
0.001
0.01
0.1
1
0 1 2
P
la
s
m
a
 c
o
n
c
e
n
tr
a
ti
o
n
 (
µ
g
/L
)
Time (h)
IV data by
Buclin et al
Curve-fitted
profile
Figure 3.10 The model-predicted profile of the plasma concentration of calcitonin vs. 
time following IV infusion. Data were taken from Buclin et al. The dashed line is the 
model-predicted profile generated using the best parameter estimates shown in Table 
3.8. 
Table 3.8 Values of the initial estimates obtained by the method of residuals and the 
best estimates derived by the curve fitting for the one-compartment model parameters 
of calcitonin from the IV PK profile data. 
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these were fixed, the lung disposition kinetic parameters, ka and knal, were floated in curve 
fitting with Scientist to be derived from each of the inhaled PK profiles of Clark et al. The 
derived ka and knal values are shown in Table 3.9, along with the goodness-of-fit 
parameters, COD and MSC. In Figure 3.11, only small deviations are shown between the 
actual data and the model-predicted profiles, demonstrating sufficient curve fitting, 
despite slightly lower MSC and COD values (Table 3.9). The lower COD and MSC values 
may be because the number of data points before the maximum plasma concentration 
(Cmax) after inhalation from DPI was just 1, and that after inhalation from NEB were only 
3, with a total of 7 data points in the sampling duration of 6 h for both devices. Such limited 
number of data points penalizes the MSC and COD values due to overparameterization 
of the model, which relies on the total number of data points as well as the data points 
around the higher concentrations available for curve fitting to derive the ka and knal values.  
 
Device ka (h-1) 
(95% CI) 
knal (h-1) 
(95% CI) 
COD*  MSC+ 
DPI 0.06 
(0.04, 0.07) 
2.32 
(1.24, 3.40) 
0.94  2.35 
NEB 0.05 
(0.04, 0.06) 
1.22 
(0.84, 1.61) 
0.97  3.00 
*Coefficient of determination; +Model selection criteria 
 
Table 3.9 The best parameter estimates for the ka and knal values of calcitonin derived 
through curve fitting of the inhaled PK profile data reported in Clark et al, along with the 
Scientist-derived goodness-of-fit parameters, COD and MSC.   
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3.3.4  Ciprofloxacin 
The IV PK profile data were taken from Brunner et al. (1999) which employed 0.17 
h infusion at a dose of 200 mg. The -scintigraphic DTL and inhaled PK data were taken 
from Stass et al. (2016) obtained following inhaled administration of spray-dried powders 
from Novartis T-326 inhaler (DPI). The subjects received charcoal orally to block 
gastrointestinal (GI) absorption of ciprofloxacin deposited in the oropharynx and 
swallowed to the GI tract. The study design and details are summarized in Table 3.10, 
which was considered comparable. The IV and inhaled PK profiles are shown in Figure 
3.12 and 3.13, respectively, while the -scintigraphic data are shown in Table 3.11. Given 
the linear PK assumption of the lung deposition and disposition PK model, literature IV 
and inhaled PK data were assessed for dose proportionality. Literature reported IV dose 
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Figure 3.11 The model-predicted profiles of the plasma concentration of calcitonin vs. 
time following inhaled DPI and NEB administration. Data were taken from Clark et al. 
The dashed lines are the model-predicted profiles generated using the best parameter 
estimates shown in Table 3.9. 
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(Brunner et al.) and DTL (Stass et al.) for DPI were assessed for linearity with the 
corresponding literature reported area under the serum and plasma concentration vs. 
time curve (AUC) and it was observed that AUC showed dose linearity. Hence it was 
assumed that ciprofloxacin followed linear PK at the reported IV dose and DTL for DPI. 
 
Literature  IV PK  
Brunner et al. 
DTL and inhaled PK  
Stass et al. 
DPI 
Subject (N) 8 12 
Gender (M/F) 8/0 12/0  
Race NR NR 
Age (years)* 28-37 21-52 
Weight (kg)+ 76 ± 4 NR 
 
Formulation dose 200 mg 32.5 mg 
Infusion time (h) 0.17 NA 
 
Sampling points (h) 0.33, 0.67, 1.00, 1.33, 1.67, 
2.00, 2.33, 2.67, 3.00, 3.33, 
3.67, 4.00, 4.33, 4.67, 5.00, 
5.33, 5.67, 6.00, 6.33, 6.67, 
7.00, 7.33, 7.67, 8.00 
0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 
Assay method High performance liquid 
chromatography with 
fluorometric detection 
Chromatography with mass 
spectrometry 
LLOQa (mg/L) 0.05 NR 
*Range; +Mean ± SE; aLower limit of quantitation; NR: Not reported; and NA: Not 
applicable 
 
Table 3.10 Study design and drug assay method for the studies used in the curve 
fitting-based lung disposition kinetic analysis for ciprofloxacin. 
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Figure 3.12 Mean (± SE) serum ciprofloxacin concentration vs. time following 0.17 h 
IV infusion at a dose of 200 mg. Data were taken from Brunner et al. (1999). 
Figure 3.13 Mean (± SD) plasma ciprofloxacin concentration vs. time following inhaled 
DPI administration. Data were taken from Stass et al. (2016). 
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Inhaler 4 ± 1 
Exhaled 1 
Extra-thoracic region  44 ± 8 
DTL  51 ± 7 
P/C ratio 0.6 
 Data: Mean ± SD; P/C ratio: Peripheral-to-central deposition ratio 
Note that the DPI formulation dose was 32.5 mg (Table 3.10) and % DTL was 51% 
(Table 3.11), thereby estimating 16.58 mg of the DTL. 
The initial estimates for the systemic disposition two-compartment model 
disposition parameters were estimated by the method of residuals on the IV PK profile 
reported in Brunner et al., as summarized in Table 3.12. The IV PK profile was then fitted 
to the two-compartment model with the initial estimates (Table 3.12) for a more accurate 
determination. The best estimates were derived as shown in Table 3.12. The fitted profile 
provided a good fit of the data as shown in Figure 3.14, and the COD was 0.99 and the 
MSC was 4.88. It was observed that k10 and VC derived by method of residuals were 
bracketed by the 95% CI of those derived by curve fitting, whereas k12 and k21 values 
derived by method of residuals were smaller than the lower level of the 95% CI of those 
derived by curve fitting. However, curve fitting derived values of parameters were 
assumed to be more accurate, as described previously. 
 
Table 3.11 % Ciprofloxacin deposition following DPI administration, measured by -
scintigraphy. Data were taken from Stass et al. (2016). 
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 Systemic PK parameter Initial estimate Best estimate 
k10 (h-1) 
(95% CI) 
0.58 0.64 
(0.57, 0.72) 
k12 (h-1) 
(95% CI) 
1.02 1.42 
(1.11, 1.73) 
k21 (h-1) 
(95% CI) 
0.64 0.86 
(0.70, 1.03) 
VC (L) 
(95% CI) 
95.4 93.2 
(84.4, 100) 
 
 
 
 
The lung disposition kinetic parameters, ka and knal, were derived by curve fitting 
the inhaled PK profiles of ciprofloxacin for DPI reported in Stass et al. The PK profile data 
was fitted to the lung disposition PK model shown in Figure 3.3, with the systemic 
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Figure 3.14 The model-predicted profile of the serum concentration of ciprofloxacin 
vs. time following IV infusion. Data were taken from Brunner et al. The dashed line is 
the model-predicted profile generated using the best parameter estimates shown in 
Table 3.12. 
Table 3.12 Values of the initial estimates obtained by the method of residuals and the 
best estimates derived by the curve fitting for the two-compartment model parameters 
of ciprofloxacin from the IV PK profile data. 
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disposition kinetic parameters fixed as described by the two-compartment model (Table 
3.12). The scintigraphic DTL was also fixed as shown in Table 3.11. The ka and knal 
values derived for DPI are shown in Table 3.13 along with 95% CI and goodness of fit 
statistics. The curve fitting provided a good fit of the data with the lung disposition model 
with the systemic PK described by the two-compartment model. The COD and MSC were 
slightly lower, while only small deviations were seen between the data and the model-
predicted profile (Figure 3.15). The lower COD and MSC values may be because there 
were no data points before the maximum plasma concentration after inhalation from DPI, 
with a total of 9 data points in the sampling duration of 8 h. Such limited number of data 
points penalizes the MSC and COD values due to overparameterization of the model, 
which relies on the total number of data points as well as the data points around the higher 
concentrations available for curve fitting to derive the ka and knal values. 
 
Device ka (h-1) 
(95% CI) 
knal (h-1) 
(95% CI) 
COD*  MSC+ 
DPI 0.98 
(0.71, 1.25) 
0.61 
(0.36, 0.86) 
0.94  2.45 
*Coefficient of determination; +Model selection criteria 
 
Table 3.13 The best parameter estimates of the ka and knal values of ciprofloxacin 
derived through curve fitting of PK profile data reported in Stass et al along with the 
Scientist-derived goodness of fit parameters, COD and MSC. 
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3.3.5  
 
3.3.5   The ka and knal values across three molecules 
Curve fitting approach was successfully used, yielding sufficient “goodness-of-fit” 
statistical parameters and deriving the ka and knal values for all the three molecules with 
small 95% CI. The curve fitting approach employed compartment model-based differential 
equations for non-linear regression of the literature PK profile data for IV and inhaled 
administration. The DTL and systemic PK parameters were fixed and only the ka and knal 
were allowed to float.  
The IV PK profile of tobramycin in healthy volunteers was also found in Haughey 
et al. (1980) and Péchère et al. (1976). However, Pleasants et al. (1988) was chosen, 
because most frequent sampling over a sufficient length of time (8 h) was taken, and the 
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Figure 3.15 The model-predicted profiles of the plasma concentration of ciprofloxacin 
vs. time following inhaled DPI administration. Data were taken from Stass et al. The 
dashed lines are the model-predicted profiles generated using the best parameter 
estimates shown in Table 3.13. 
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assay method was reliable and same as that used in Newhouse et al. (2003). Haughey 
et al. and Péchère et al. both used a microbiological assay. Besides, Haughey at al. 
(1980) reported the PK profile from just one volunteer. The inhaled PK profiles of 
tobramycin were also found in Pilcer et al. (2008), but in cystic fibrosis (CF) patients. 
Given the pathophysiology of CF lungs, inhaled drug disposition kinetics were likely 
affected by the disease condition. For calcitonin and ciprofloxacin, an exhaustive literature 
search could not find other IV or inhaled PK profiles in healthy volunteers or the 
corresponding -scintigraphy-based lung deposition data.  
Byron and Patton (1994) proposed the following equation with an assumption that 
lung absorption undergoes passive diffusion via partitioning through cell membranes: 
ka= DM*AM*KD/(h*VLLF)                                                                         Equation 3.4 
where DM is the diffusion coefficient through lung membrane, AM is the total lung 
membrane surface area, KD is the drug partition/distribution coefficient, h is the thickness 
of lung membrane and VLLF is the lung lining fluid (LLF) volume. Assuming the 
physiological parameters AM, h and VLLF as constant, ka now becomes dependent on 
DM*KD and given that DM is proportional to 1/(MW)1/3 as per the Stokes-Einstein equation, 
ka is now dependent on KD/(MW)1/3. Therefore, the derived ka values were plotted against 
the respective KD/(MW)1/3, yielding equation log [ka] = 0.05 + 0.04 x log [KD/(MW)1/3] (R2= 
0.99) which found a good correlation, as shown in Figure 3.16-A. However, given the log-
log plot, the equation implies that ka is proportional to KD/(MW)1/3 only when it is raised to 
power 0.04 (slope).  
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Figure 3.16-A implies that ka is not proportional to KD/(MW)1/3 unless it was raised 
to a power of 0.04. It may be because all the molecules are hydrophilic in nature with 
negative log KD values. Thus, assuming ka to be independent of KD in case of these three 
hydrophilic molecules, ka was plotted against 1/(MW)1/3 only, as can be seen in Figure 
3.16-B yielding equation log [ka] = 2.6 + 3.0 x log [1/(MW)1/3] (R2= 0.96) which also found 
a good correlation. However, given the log-log plot, the equation implies that ka is 
proportional to 1/(MW)1/3 only when it is raised to power 3 (slope). This in turn implies that 
for tobramycin, calcitonin and ciprofloxacin, ka is proportional to 1/(MW), indicating that 
their molecular weight appears to primarily control their absorption kinetics from the lung. 
That is, for large hydrophilic calcitonin, the ka value was the smallest, followed by small 
hydrophilic tobramycin, and finally, smaller hydrophilic ciprofloxacin. Ciprofloxacin is a 
substrate for active transport through bronchial epithelium by OCTs and OATP2B1 (Ong 
Figure 3.16-A Correlation between ka and KD/(MW)1/3 for tobramycin, calcitonin and 
ciprofloxacin. 
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et al. 2013), and so even though Figure 3.16-B implies ciprofloxacin absorption kinetics 
being primarily controlled by its MW, the derived high ka value may also be confounded 
by its active uptake through the central lung, which is consistent with its low P/C ratio of 
0.6 indicating its deposition primarily in the central lung. 
 
 
 
 
The drug’s solubility may also play an important role in its absorption rate, and if 
so, their lung absorption kinetics could be dissolution controlled, especially for small 
lipophilic molecules like fluticasone propionate (Sakagami 2014). However, the aqueous 
solubility values for tobramycin, calcitonin and ciprofloxacin (Table 3.1) are adequately 
high and therefore, it is unlikely that their absorption was rate-limited by 
solubility/dissolution. 
Figure 3.16-B Correlation between ka and 1/(MW)1/3 for tobramycin, calcitonin and 
ciprofloxacin. 
 
 
47 
 
The ka values also seemed to be dependent on inhaler device as seen for 
tobramycin. Different inhalers resulted in different regional lung deposition and 
accordingly, different ka values presumably due to different regional lung deposition. It 
can be seen that a higher P/C ratio, which indicates a greater fractional deposition in the 
peripheral (deeper) lung, produced a greater ka value, in line with our conventional belief 
that absorption is faster from the peripheral (deeper) lung by virtue of greater perfusion 
and thinner pulmonary membranes. 
The knal values for the three drugs were derived in a wide range of 0.08-2.32 h-1, 
and seemed to be drug dependent. Byron (1986) and Gonda (1988) reported 0.4-0.7 h-1 
as first order rate constant of mucociliary clearance from central lung (kmcc) and 0.17 h-1 
as first order rate constant of mucociliary clearance from peripheral lung (kmcp) in humans. 
(Sakagami 2004) The knal values for calcitonin were greater than that of kmcc and kmcp 
values, perhaps due to local lung metabolism by proteolysis, as similarly suggested for 
the knal values for inhaled insulin by Sakagami (2004). On the other hand, the knal values 
for tobramycin were smaller than the kmcc and kmcp values, which might be associated with 
lung tissue binding of this drug which will be polycationic in nature at physiological pH. Li 
and Byron (2013) suggested the lung tissue binding of polycationic tobramycin in the 
isolated perfused rat lung (IPRL) at 0.02-100 mg/ml. With 10-30 ml of the lung surface 
fluid, 27.4 mg of tobramycin in DTL would result in 0.91–2.74 mg/ml of the lung surface 
concentration. Thus, it is possible that tobramycin is highly bound in the lungs. However, 
Li and Byron (2003) describe tobramycin’s binding as a biphasic process, involving 
sequestration/binding followed by a slow desequestration/dissociation, which implies that 
it may be released from the lung tissue in a time-dependent manner, and this released 
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fraction will then be available for absorption and non-absorptive clearance pathways 
including mucociliary clearance. Thus, caution must be exercised when interpreting the 
0.08 h-1 of the derived knal values of tobramycin as caused by tissue binding alone, 
because the lung deposition and disposition model (Figure 3.3) does not account for such 
time-dependent slow desequestration/dissociation of tobramycin. In that respect, the knal 
value for ciprofloxacin was found comparable to the kmcc value, which was consistent with 
its lack of local lung metabolism and lung tissue binding.  
 
Drug MW 
(Da) 
Log 
KD 
Inhaler 
device 
P/C 
ratio 
ka (h-1) 
(95% CI) 
knal (h-1) 
(95% CI) 
Tobramycin 468 -10 DPI 1.6±0.4 0.45 
(0.35, 0.55) 
0.08 
(0.02, 0.17) 
   NEB 1.5±0.4 0.34 
(0.28, 0.40) 
0.08 
(0.01, 0.15) 
Calcitonin 3,432 -33 DPI 0.8±0.3 0.06 
(0.04, 0.07) 
2.32 
(1.24, 3.40) 
   NEB 1.4±0.3 0.05 
(0.04, 0.06) 
1.22 
(0.84, 1.61) 
Ciprofloxacin 331 -2 DPI 0.6 0.98 
(0.71, 1.25) 
0.61 
(0.36, 0.86) 
P/C ratio: Peripheral-to-central deposition ratio 
 
3.4  Conclusions 
Using inhaled and IV PK profiles alongside DTL from the lung deposition data in 
the literature, the lung disposition kinetic descriptors (ka and knal) in humans were 
successfully derived for three drugs delivered by DPI and/or NEB via curve fitting. The ka 
Table 3.14 Physicochemical properties and the ka and knal values derived by curve 
fitting for tobramycin, calcitonin and ciprofloxacin. 
 
 
49 
 
values were found to be dependent on the drug’s MW, as passive diffusion appeared to 
be the predominant pathway for these drugs’ absorption. However, regional lung 
deposition influenced the ka values in case of tobramycin, and the greater ka value was 
seen with higher P/C ratio, i.e., greater deposition in the peripheral lung. While the knal 
values did not seem to depend on the physicochemical properties, physiological 
processes such as local lung tissue binding, metabolism and mucociliary clearance seem 
to affect the knal values. The knal value for ciprofloxacin was consistent with the kmcc and 
the lung tissue binding may have decreased the knal value for tobramycin. In contrast, 
calcitonin is a peptide and thus highly susceptible to proteolytic degradation by proteases 
in the lung, including trypsin, chymotrypsin and aminopeptidase. This may have 
contributed to its high knal values.  
The ka values were shown to be well correlated with the drug’s MW, while also 
being affected by regional deposition within the lung.  The knal values were determined by 
the presence of binding, local metabolism and mucociliary clearance. While similar 
attempts should continue with different drugs, these results have suggested that this 
curve fitting approach seems to be useful in deriving the accurate descriptors that 
determine the lung disposition kinetics and predicting the lung kinetic behavior of new 
drug entities in humans.   
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CHAPTER 4 
LUNG DISPOSITION KINETIC ANALYSIS VIA MOMENT-BASED APPROACH 
 
 
 
4.1  Introduction  
In Chapter 3, the inhaled PK profile data for three inhaled drugs (tobramycin, 
calcitonin and ciprofloxacin) were analyzed with the lung deposition and disposition 
compartment model by curve fitting approach. As a result, the kinetic descriptors of lung 
absorption (ka) and non-absorptive loss (knal) were reasonably determined. In this chapter, 
the same PK data sets were used with a different approach of the moment-based 
analyses. The same lung disposition kinetic model was then applied to derive the ka and 
knal values. The ka and knal values derived by these two different methods were finally 
compared and discussed. 
 
4.2  Methods 
4.2.1  Literature data collection 
The IV PK profile data and the inhaled -scintigraphy and PK profile data for 
tobramycin, calcitonin and ciprofloxacin were those taken from the literature and used in 
the curve fitting-based analysis of the lung disposition kinetics described in Chapter 3. 
Table 4.1 lists the respective literature sources for each drug. The mean plasma/serum 
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drug concentration vs. time profile data were extracted using GetData Graph Digitizer, as 
completed in Chapter 3. 
 
 
 
4.2.2  Moment-based analyses for IV and inhaled PK profiles  
Moment-based PK profile analyses were carried out, as described in Gibaldi & 
Perrier (1982). The total area under the plasma/serum concentration vs. time profile curve 
(AUCtot) was first calculated by: 
AUCtot = AUC0-last + AUClast-∞                          Equation 4.1 
where AUC0-last is the AUC between time 0 and the last sampling time (tlast), calculated by 
the trapezoidal method; and AUClast-∞ is the extrapolated AUC after the last sampling time 
up to time infinity, which was calculated by: 
AUClast-∞ = CClast /                             Equation 4.2 
where CClast is the plasma/serum concentration at the last sampling time; and  is the 
terminal-phase slope in the semi-natural logarithmic plasma/serum concentration vs. time 
plot. Separately, the total area under the moment plasma/serum concentration vs. time 
profile curve (AUMCtot) was calculated by: 
AUMCtot = AUMC0-last + AUMClast-∞                         Equation 4.3 
Drug IV PK Inhaled -scintigraphy and PK 
 
Tobramycin Pleasants et al., 1988 Newhouse et al., 2003 
Calcitonin Buclin et al., 2002 Clark et al., 2008 
Ciprofloxacin Brunner et al., 1999 
 
Stass et al., 2016 
Table 4.1 Literature used in the moment-based lung disposition kinetics analyses. 
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where AUMC0-last is the AUMC between time 0 and the last sampling time (tlast), calculated 
with the profile of [CC x time] vs. time by the trapezoidal method; and AUMClast-∞ is the 
extrapolated AUMC after the last sampling time up to time infinity, which was calculated 
by: 
AUMClast-∞ = (CClast / 2) + (CClast ∙ tlast / )                                   Equation 4.4 
Accordingly, the mean residence time (MRT) after administration was calculated by: 
MRT = AUMCtot / AUCtot - Tdose / 2                        Equation 4.5 
where Tdose is the time required for constant rate administration, i.e., time of infusion or 
nebulization and otherwise 0 for IV bolus and inhaled administration with DPI (or pMDI). 
From the IV and inhaled PK profile data, the MRT values were respectively determined 
by the method described above, as MRTiv and MRTinh. 
 
4.2.3  Moment-based determination of lung disposition kinetic parameters  
To analyze the lung disposition kinetics with these MRT values, the lung 
disposition kinetic model used in the curve fitting approach in Chapter 3 and now shown 
in Figure 4.1 was used in following the moment-based analysis described above. Given 
the linear PK assumption, the MRT in the lung (MLRT) was calculated by: 
MLRT = MRTinh - MRTiv                                         Equation 4.6 
Now, in the model shown in Scheme 4.1, the lung absorption and non-absorptive loss 
were kinetically rate-controlled with the respective rate constants, ka and knal, as assumed 
in Chapter 3. Hence, by definition, the MLRT was described by: 
 MLRT = 1 / (ka + knal)                            Equation 4.7 
Notably, the fractional bioavailability of inhaled administration (FL) was also defined by: 
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FL = ka / (ka + knal)                              Equation 4.8 
Therefore, from Equations 4.7 and 4.8, the ka and knal values were estimated with: 
 ka = FL / MLRT                                             Equation 4.9 
           knal = 1 / MLRT – ka                         Equation 4.10  
It should be noted that the FL value was calculated with the AUC values normalized with 
dose for IV and inhaled administration, as described below: 
 FL = (AUCtot,inh/DTL) / (AUVtot,iv/Doseiv)                      Equation 4.11 
where Doseiv is the IV dose by bolus injection or infusion; and DTL is the dose to the lung 
determined from -scintigraphy. 
 
 
 
 
 
 
 
 
 
 
 
ka 
knal 
Systemic disposition 
elimination 
Lung 
DTL 
Figure 4.1 The lung deposition and disposition model that incorporates absorption and 
non-absorptive loss, along with the systemic elimination. The lung receives dose-to-
the lung (DTL) upon inhaled administration. Lung’s absorption and non-absorptive loss 
are kinetically described with the first-order rate constants, ka and knal, respectively. 
The systemic disposition kinetics were controlled not only with elimination from the 
systemic circulation but also by lung absorption as the first-order input rate, ka. 
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4.3  Results and Discussion 
4.3.1  Tobramycin 
The moment-based analyses of the IV and inhaled PK profile data for tobramycin 
are summarized in Table 4.2. The derived lung disposition kinetic parameters, ka and knal, 
are shown in Table 4.3 and compared with those derived by the curve fitting approach in 
Chapter 3, as shown in Table 4.4. The ka and knal values for tobramycin inhaled with the 
DPI and NEB were each bracketed by the 95% CI of the corresponding rate constant 
values derived by the curve fitting approach.  
PK parameter IV Inhalation 
DPI NEB 
AUC0-last (mg/L*h) 17.8 3.37 1.65 
Terminal slope  (h-1) 0.32 0.27 0.30 
AUClast-∞ (mg/L*h) 1.40 0.85 0.40 
AUCtot (mg/L*h) 19.2 4.22 2.05 
AUMC0-last (mg/L*h2) 41.6 11.9 6.02 
AUMClast-∞ (mg/L*h2) 15.6 10.0 4.56 
AUMCtot (mg/L*h2) 57.2 21.9 10.6 
MRT (h) 2.73 5.06 5.04 
 
Lung disposition kinetic 
parameter 
DPI NEB 
MLRT (h) 2.34 2.32 
1/MLRT (h-1) 0.43 0.43 
FL 0.94 0.84 
ka (h-1) 0.40 0.36 
knal (h-1) 0.03 0.07 
Table 4.3 The lung disposition kinetic parameters for tobramycin derived through the 
moment-based analyses.  
Table 4.2 The IV and inhaled PK parameters for tobramycin in the moment-based 
analyses. 
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Device 
ka (h-1) 
(95% CI) 
knal (h-1) 
(95% CI) 
Curve 
fitting 
Moment 
analysis 
Curve 
fitting 
Moment 
analysis 
DPI 0.45 
(0.35, 0.55) 
0.40 0.08 
(0.02, 0.17) 
0.03 
NEB 0.34 
(0.28, 0.40) 
0.36 0.08 
(0.01, 0.15) 
0.07 
 
 
4.3.2  Calcitonin 
The moment-based analyses of the IV and inhaled PK profile data for calcitonin 
are summarized in Table 4.5. The derived lung disposition kinetic parameters ka and knal 
are shown in Table 4.6 and compared with those derived by the curve fitting approach in 
Chapter 3, as shown in Table 4.7. The knal values for calcitonin inhaled with the DPI and 
NEB were each bracketed by the 95% CI of the knal values derived by the curve-fitting 
approach. However, the ka values derived were outside the 95% CI of the ka values 
derived by the curve fitting approach. Notably, these values were greater than the upper 
side of the 95% CI.  
 
 
 
Table 4.4 The ka and knal values of tobramycin derived by the curve fitting- and moment-
based approaches. 
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PK parameter IV Inhalation 
DPI NEB 
AUC0-last (µg/L*h) 0.16 0.05 0.07 
Terminal slope  (h-1) 3.72 0.85 0.77 
AUClast-∞ (µg/L*h) 0 0 0 
AUCtot (µg/L*h) 0.16 0.05 0.07 
AUMC0-last (µg/L*h2) 0.12 0.05 0.09 
AUMClast-∞ (µg/L*h2) 0 0 0 
AUMCtot (µg/L*h2) 0.12 0.05 0.09 
MRT (h) 0.28 0.96 1.21 
 
Lung disposition kinetic 
parameter 
DPI NEB 
MLRT (h) 0.68 0.93 
1/MLRT (h-1) 1.47 1.08 
FL 0.07 0.08 
ka (h-1) 0.10 0.09 
knal (h-1) 1.37 0.99 
 
 
Device 
ka (h-1) 
(95% CI) 
knal (h-1) 
(95% CI) 
Curve 
fitting 
Moment 
analysis 
Curve 
fitting 
Moment 
analysis 
DPI 0.06 
(0.04, 0.07) 
0.10 2.32 
(1.24, 3.40) 
1.37 
NEB 0.05 
(0.04, 0.06) 
0.09 1.22 
(0.84, 1.61) 
0.99 
 
 
Table 4.6 The lung disposition kinetic parameters for calcitonin derived through the 
moment-based analyses. 
Table 4.7 The ka and knal values of calcitonin derived by the curve fitting and moment-
based approaches. 
Table 4.5 The IV and inhaled PK parameters for calcitonin in the moment-based 
analyses. 
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4.3.3  Ciprofloxacin 
The moment-based analyses of the IV and inhaled PK profile data for ciprofloxacin 
are summarized in Table 4.8. The contribution of AUClast-∞ to AUCtot was 26%, greater 
than the gold standard of 20%. This may be because of insufficient sampling duration and 
not the sampling intervals, because Brunner et al. employed sufficient number of 
sampling intervals over the 8 h sampling duration. The derived lung disposition kinetic 
parameters ka and knal are shown in Table 4.9 and compared with those derived by the 
curve fitting approach in Chapter 3, as shown in Table 4.10. The ka value for ciprofloxacin 
inhaled with the DPI was bracketed by the 95% CI of the corresponding rate constant 
value derived by the curve fitting approach. However, the knal value derived was outside 
the 95% CI of the knal value derived by the curve fitting approach. Notably, this value was 
smaller than the lower side of the 95% CI.  
 
PK parameter IV Inhalation 
DPI 
AUC0-last (mg/L*h) 2.39 0.18 
Terminal slope  (h-1) 0.18 0.17 
AUClast-∞ (mg/L*h) 0.85 0.03 
AUCtot (mg/L*h) 3.25 0.21 
AUMC0-last (mg/L*h2) 6.92 0.75 
AUMClast-∞ (mg/L*h2) 11.6 0.59 
AUMCtot (mg/L*h2) 18.5 1.35 
MRT (h) 5.61 6.39 
 
Table 4.8 The IV and inhaled PK parameters for ciprofloxacin in the moment-based 
analyses. 
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Lung disposition kinetic parameter DPI 
MLRT (h) 0.78 
1/MLRT (h-1) 1.28 
FL 0.78 
ka (h-1) 1.00 
knal (h-1) 0.28 
 
 
 
 
Device 
ka (h-1) 
(95% CI) 
knal (h-1) 
(95% CI) 
Curve 
fitting 
Moment 
analysis 
Curve 
fitting 
Moment 
analysis 
DPI 0.98 
(0.71, 1.25) 
1.00 0.61 
(0.36, 0.86) 
0.28 
 
 
4.4 Comparison between moment-based analysis and curve fitting-based 
approaches 
Moment analysis-based approach was successfully used to derive the ka and knal 
values for all three drugs. This approach employed the same IV and inhaled PK profile 
data as those used in the curve fitting-based approach in Chapter 3. The approach used 
integrated equations to calculate the AUC and AUMC of the plasma/serum concentration-
time curves, followed by the use of the lung disposition PK model to derive the ka and knal 
values. In contrast, the curve fitting approach used differential equation-based non-linear 
regression, in which IV PK parameters were fixed to derive the ka and knal values. Note 
Table 4.9 The lung disposition kinetic parameters for ciprofloxacin derived by the 
moment-based analyses. 
Table 4.10 The ka and knal values of ciprofloxacin derived by the curve fitting- and 
moment-based approaches. 
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that, in the curve fitting, the ka and knal values were derived by fitting the PK profile data 
up to the last sampling time point (tlast).  
The ka and knal values for tobramycin (both DPI and NEB) and ka value for 
ciprofloxacin (DPI) were each derived within the 95% CI of the corresponding rate 
constant values for the curve fitting approach. The knal values for calcitonin (DPI/NEB) 
were also within the 95% CI of the values for the curve fitting approach. However, the ka 
values for calcitonin (both DPI and NEB) and knal value for ciprofloxacin were outside the 
95% CI of the respective values derived by the curve fitting approach. In fact, calcitonin 
ka values were greater than the upper side of the 95% CI and ciprofloxacin knal value was 
lower than the lower side of the 95% CI. It is speculated that this over-estimation of the 
ka values and under-estimation of the knal values by the moment analysis-based approach 
may be due to its use of the AUC and AUMC beyond the tlast.  
Despite the slight inconsistencies in the values derived by the curve fitting- and 
moment analysis-based approaches as described above, it was observed that the ka 
values derived by moment analysis still found a good correlation with the 1/(MW)1/3 of the 
drug molecules when plotted alongside the curve fitting-based ka values, as depicted in 
Figure 4.1, yielding equation log [ka] = 2.3 + 3.0 x log [1/(MW)1/3] (R2= 0.92). 
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4.5  Conclusions 
Using the inhaled and IV PK profiles alongside the DTL from the scintigraphic 
lung deposition data in the literature, the lung disposition kinetic descriptors (ka and knal) 
were successfully derived for the three drugs delivered by DPI and/or NEB via the 
moment analysis-based approach. The values derived by these two approaches are 
summarized in Table 4.11. In addition, the ka and knal values were comparable to those 
derived by the curve fitting-based approach in the majority of the cases. Thus, it is now 
possible to derive the lung disposition kinetics by this moment analysis-based approach, 
even though the data set are not compatible to the curve fitting approaches such as when 
AUC and MRT are the only available information pertinent to a drug molecule. However, 
the curve fitting approach can give statistical information like 95% CI, COD and MSC, and 
therefore, would provide greater confidence in their derived values.
Figure 4.2 Correlation between curve fitting- and moment analysis-based ka and 
1/(MW)1/3 for tobramycin, calcitonin and ciprofloxacin. 
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Drug MW 
(Da) 
Log 
K
D
 
Inhaler 
device 
P/C 
ratio 
k
a 
(h
-1
) (95% CI) k
nal
 (h
-1
) (95% CI) 
Curve fitting Moment analysis Curve fitting Moment analysis 
Tobramycin 468 -10 DPI 1.6±0.4 0.45 
(0.35, 0.55) 
0.40 0.08 
(0.02, 0.17) 
0.03 
   NEB 1.5±0.4 0.34 
(0.28, 0.40) 
0.36 0.08 
(0.01, 0.15) 
0.07 
Calcitonin 3,432 -33 DPI 0.8±0.3 0.06 
(0.04, 0.07) 
0.10 2.32 
(1.24, 3.40) 
1.37 
NEB 1.4±0.3 0.05 
(0.04, 0.06) 
0.09 1.22 
(0.84, 1.61) 
0.99 
Ciprofloxacin 331 -2 DPI 0.6 0.98 
(0.71, 1.25) 
1.00 0.61 
(0.36, 0.86) 
0.28 
P/C ratio: Peripheral-to-central deposition ratio
Table 4.11 Physiochemical properties and the ka and knal values derived by the curve fitting and moment analysis 
approaches for tobramycin, calcitonin and ciprofloxacin. 
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Chapter 5 
EFFECTS OF LUNG DELIVERY AND DISPOSITION KINETIC CHANGES ON 
SYSTEMIC PK AND LUNG EXPOSURE PROFILES VIA SIMULATION 
 
 
 
5.1  Introduction 
In Chapters 3 and 4, the inhaled PK profile data for the three drugs, tobramycin, 
calcitonin and ciprofloxacin, have successfully derived the kinetic descriptors for lung 
disposition by the curve fitting and moment-based approaches, respectively. In both 
approaches, the identical kinetic compartment model was assumed for lung disposition, 
thereby resulting in plausible and comparable kinetic rate constants for lung absorption 
(ka) and non-absorptive loss (knal). However, only the mean PK profile data were used, so 
that how variance of the PK profile data affects derivation of these kinetic descriptors is 
uncertain. Conversely, from the bioequivalence regulation perspective, how variance or 
difference of each of the kinetic descriptors affects the systemic PK and local lung 
exposure profile outcomes would be of interest in order to identify the key attribute(s) 
within the lung. Hence, this chapter used the kinetic rate constants derived through the 
curve fitting in Chapter 3 as the reference standard conditions and simulated the PK and 
lung exposure profiles upon a 20 % positive or 20 % negative change in each of the DTL, 
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ka and knal values. By so doing, likely changes in the model’s predictions for the 
plasma/serum PK metrics, Cmax, AUC and Tmax, and for the local lung exposure metrics, 
AUClung (area under the drug mass in the lung vs. time curve) and LRT0.5 (lung residence 
half-life), were identified and discussed for each of the three drugs.       
 
5.2  Methods 
5.2.1  Models and reference standard conditions 
Figure 5.1 describes the kinetic models and their model parameters and the DTL 
used as the reference standard conditions for A) tobramycin, B) calcitonin and C) 
ciprofloxacin. These were derived in Chapter 3 as the parameter estimates to best explain 
each of the inhaled PK profiles of the literature. Note that the model parameters for 
tobramycin and calcitonin were those for DPI, like ciprofloxacin.  
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0.08 h-1 
0.45 h-1 
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0.36 h
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0.69 h
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0.53 h
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compartment 
11.4 L 
A. Tobramycin 
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Lung 
2.32 h-1 
0.06 h-1 
52.9 µg 
3.72 h
-1
 
Central  
compartment 
17.9 L 
Lung 
0.61 h-1 
0.98 h-1 
16.58 mg 
1.42 h
-1
 
0.86 h
-1
 
0.64 h
-1
 
Central  
compartment 
Peripheral  
compartment 
93.2 L 
B. Calcitonin 
C. Ciprofloxacin 
Figure 5.1 The kinetic models and their parameters and the DTL used as the reference 
standard conditions for A) tobramycin, B) calcitonin and C) ciprofloxacin. These 
parameters were derived in Chapter 3 as the parameter estimates to best explain each 
of the inhaled PK profiles of the literature. 
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5.2.2   Systemic PK profile simulation upon ±20 % changes of the DTL, ka and knal 
With the models shown above, the DTL, ka and knal values were each changed to 
a 20 % positive or a 20 % negative value, and the plasma/serum PK profiles were then 
predicted by simulation using Scientist. All the remaining parameters were fixed, as 
shown in Fig. 5.1. Simulation prediction was made every 1 min over the period of 8 h for 
tobramycin and ciprofloxacin and 6 h for calcitonin, as used in the literature. The Cmax and 
Tmax were identified from the predicted profile data, while the AUC was calculated by the 
trapezoidal method plus the residual area calculation, as described in Chapter 4.  
 
5.2.3  Local lung exposure profile simulation upon ±20 % changes of the DTL, ka 
and knal 
From the kinetic models shown in Figure 5.1, the drug mass remaining in the lung 
(ML) at a given time was described by:  
dML/dt = -(ka+knal)*ML                                                           Equation 5.1 
where ML was DTL at time 0, i.e., immediately after inhaled administration. Hence, the 
local lung exposure profiles were predicted by simulation with the ka and knal values and 
the DTL with or without positive and negative 20 % changes using Scientist. Like the 
systemic PK profile simulation, simulation prediction was made every 1 min over the 
period of 8 h for tobramycin and ciprofloxacin and 6 h for calcitonin, as used in the 
literature. With the predicted profile data, the AUClung (area under the drug mass in the 
lung vs. time curve) was calculated by the trapezoidal method plus the residual area 
calculation; and the LRT0.5 (lung residence half-life) was by: 
LRT0.5 = 0.693 / (ka+knal)                                               Equation 5.2 
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Graphically, the slope of the semi-natural logarithmic local lung exposure profile 
corresponded to the (ka+knal) value.  
 
5.3  Results and Discussion 
5.3.1  Systemic PK profile simulation upon ±20 % changes of the DTL, ka and knal 
5.3.1.1 Tobramycin 
 The simulation results of ±20 % changes of the DTL, ka and knal to the serum 
concentration vs. time profile and its PK metrics for tobramycin are shown in Figure 5.2-
A. When the DTL was changed by ±20 %, the Cmax and AUC∞ were identically changed 
by ±20 %, respectively, while the Tmax was unchanged. These identical changes in the 
Cmax and AUC∞ were simply a reflection of linear lung disposition and systemic kinetics 
and PK. The ±20 % changes in the ka resulted in 11 or 13 % changes in the Cmax, 3 or 5 
% changes in the AUC∞ and 9 or 11 % changes in the Tmax. This indicated that the Cmax 
and Tmax were more influenced by changes in the ka than the AUC∞. This may be 
attributed to the fact that the Cmax (a measure of the rate and extent of absorption) and 
Tmax (a measure of rate of absorption) were primarily determined by the sum of the ka and 
knal, but for tobramycin, the ka was a predominant contributor (by 85 %). It should be noted 
that the positive and negative 20 % changes did not give identical % changes in any of 
the parameters. The 20 % changes in knal (i.e., the minor contributor) resulted in only 
small 2-4 % changes in the Cmax, AUC∞ and Tmax. 
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5.3.1.2 Calcitonin 
The simulation results of ±20 % changes of the DTL, ka and knal to the plasma 
concentration vs. time profile and its kinetic parameters for calcitonin are shown in Figure 
5.2-B. As seen for tobramycin, the ±20 % changes in DTL caused identical ±20 % 
changes in the Cmax and AUC∞, but no change in the Tmax. Similarly, the ±20 % changes 
in the ka resulted in ±20 % changes in the Cmax and AUC∞, but again no changes in the 
Tmax. This may be because, for calcitonin, the ka is a significantly minor contributor of 
ka+knal, so that the ±20 % changes in the ka did not cause significant changes to the rate 
of absorption. While the Cmax and AUC∞ were suggested to be more influenced by the 
changes in the ka than the Tmax, these changes were different from the changes seen for 
tobramycin, presumably because of the fact that the ka was much smaller than the knal for 
calcitonin and thus, the ka changes did not cause changes in the sum of the ka and knal. 
In contrast, the ±20 % changes in the knal resulted in 8 or 9 % changes in the Cmax, 16 or 
24 % changes in the AUC∞, and 10 % changes in the Tmax. These changes in the kinetic 
parameters were likely because the sum of the ka and knal changed by a greater extent 
with the changes in the knal.  
 
5.3.1.3 Ciprofloxacin 
The simulation results of ±20 % changes of the DTL, ka and knal to the plasma 
concentration vs. time profile and its kinetic parameters for ciprofloxacin are shown in 
Figure 5.2-C. When the DTL was changed by ±20 %, the Cmax and AUC∞ were identically 
changed by ±20 %, respectively, while the Tmax was unchanged. These identical changes 
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in the Cmax and AUC∞ were simply a reflection of linear lung disposition kinetics and PK. 
The ±20 % changes in the ka resulted in 13 or 15 % changes in the Cmax, 7 or 9 % changes 
in the AUC∞ and 8 or 10 % changes in the Tmax. This indicated that the Cmax and Tmax 
were marginally more influenced by changes in the ka than the AUC∞. This may again be 
attributed to the fact that the Cmax (a measure of the rate and extent of absorption) and 
Tmax (a measure of rate of absorption) were primarily determined by the sum of the ka and 
knal, but for ciprofloxacin, the ka was a predominant contributor (by 62 %). Note that the 
positive and negative 20 % changes did not give identical % changes in any of the 
parameters. The 20 % changes in the knal (the minor contributor) resulted in smaller ~4 
% changes in the Cmax and 5 % changes in the Tmax.  
 
5.3.1.4. Systemic PK profile simulation for three molecules 
Across three molecules, when the ka was increased, the AUC∞ (i.e., the extent of 
absorption) was increased. In general, increasing either the ka or knal causes the sum of 
the ka and knal, i.e., (ka+knal), to be increased, and because the (ka+knal) determines the 
rate of absorption, increasing either the ka or knal shortened the Tmax. Because the Cmax is 
determined by both the rate and extent of absorption, changes in either the ka or knal 
changed the Cmax. For calcitonin, the ka was ~3 % of the (ka+knal) and hence, changes in 
the ka didn’t much change the (ka+knal). This may also be the reason for no changes in 
the Tmax in response to the ka changes. For the simplest case scenario of a bolus DPI 
inhalation and one-compartment model shown for calcitonin in Figure 5.1-B, the Tmax and 
Cmax are described by the following equation as derived from Gibaldi & Perrier (1982): 
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Tmax=      2.303          * log  (ka+knal)                                                                 Equation 5.1    
           (ka+knal) – k10             k10 
 
Cmax= FL * DTL e- k10*Tmax                                                                                Equation 5.2 
                      VC 
where k10 is the first-order elimination rate constant from the central compartment and FL 
is fractional pulmonary bioavailability. Thus, for calcitonin, the ka or knal increase led to an 
increase in the (ka+knal) and subsequently to a shorter Tmax. Similar analogy may be 
applied to a bolus DPI inhalation and two-compartment model, wherein, an increase in 
(ka+knal) led to a shorter Tmax. 
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Figure 5.2-A Effects of ±20 % changes in the A) DTL, B) ka and C) knal values on the serum tobramycin concentration vs. 
time profiles following inhaled administration in healthy subjects and % changes in the Cmax, AUC∞ and Tmax values. The 
profiles in blue are drawn by simulation using DTL= 27.4 mg, ka= 0.45 h-1 and knal= 0.08 h-1, as derived by the curve-
fitting of the profile data in the literature in Chapter 3. The profiles in orange and gray are drawn by simulation upon +20 
and -20 % change in the parameter of interest, while the remainders were held consistent with the values derived through 
the curve-fitting. 
A. DTL  B. ka C. knal 
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A. DTL  B. ka C. knal 
Figure 5.2-B Effects of ±20% changes in the A) DTL, B) ka and C) knal values on the plasma calcitonin concentration vs. 
time profiles following inhaled administration in healthy subjects and % changes in the Cmax, AUC∞ and Tmax values. The 
profiles in blue are drawn by simulation using DTL= 52.9 µg, ka= 0.06 h-1 and knal= 2.32 h-1, as derived by the curve-
fitting of the profile data in the literature in Chapter 3. The profiles in orange and gray are drawn by simulation upon +20 
and -20 % change in the parameter of interest, while the remainders were held consistent with the values derived 
through the curve-fitting. 
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A. DTL  B. ka C. knal 
Figure 5.2-C Effects of ±20% changes in the A) DTL, B) ka and C) knal values on the plasma ciprofloxacin concentration 
vs. time profiles following inhaled administration in healthy subjects and % changes in the Cmax, AUC∞ and Tmax values. 
The profiles in blue are drawn by simulation using DTL= 16.58 mg, ka= 0.98 h-1 and knal= 0.61 h-1, as derived by the 
curve-fitting of the profile data in the literature in Chapter 3. The profiles in orange and gray are drawn by simulation upon 
+20 and -20 % change in the parameter of interest, while the remainders were held consistent with the values derived 
through the curve-fitting. 
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5.3.2  Local lung exposure profile simulation upon ±20 % changes of the DTL, ka 
and knal 
5.3.2.1 Tobramycin 
Figure 5.3-A shows the simulation results of ±20 % changes of the DTL, ka and knal 
to the tobramycin mass remaining in the lung vs. time profiles and lung exposure kinetic 
parameters, AUClung and LRT0.5. When the DTL was changed by ±20 %, the AUClung was 
identically changed by ±20 %, while the LRT0.5 was unchanged, as similarly seen in the 
PK profile in Figure 5.2-A. In contrast, with the ±20 % changes in the ka, both the AUClung 
and LRT0.5 changed by 14 or 19 % and 15 or 21 %, respectively. However, with the ±20 
% changes in the knal, the changes in the AUClung and LRT0.5 were small and ~4 %. These 
may be again consistent with the fact that, for tobramycin, the ka was kinetically a 
predominant contributor (by 85 %) in the lung exposure profile, given its rate-control by 
the sum of the ka and knal. 
 
5.3.2.2 Calcitonin  
Figures 5.3-B shows the simulation results of ±20 % changes of the DTL, ka and 
knal to the calcitonin mass remaining in the lung vs. time profiles and lung exposure kinetic 
parameters, AUClung and LRT0.5. As was the case for tobramycin, the ±20 % changes in 
the DTL identically changed the AUClung by ±20 %, while the LRT0.5 was unchanged. With 
the ±20 % changes in the ka, both the AUClung and LRT0.5 changed by only 0.5 %. 
However, with the ±20 % changes in the knal, the changes in both AUClung and LRT0.5 
were much greater, 16 or 24 %. These were consistent with the fact that, for calcitonin, 
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the knal was kinetically a predominant contributor (by 97.5 %) in the lung exposure profile, 
given its rate control by the sum of the ka and knal. 
 
5.3.2.3 Ciprofloxacin 
Figure 5.3-C shows the simulation results of ±20 % changes of the DTL, ka and 
knal to the ciprofloxacin mass remaining in the lung vs. time profiles and lung exposure 
kinetic parameters, AUClung and LRT0.5. When the DTL was changed by ±20 %, the 
AUClung was identically changed by ±20 %, while the LRT0.5 was unchanged. In contrast, 
with the ±20 % changes in the ka, both the AUClung and LRT0.5 changed by 11 or 14 %. 
However, with the ±20 % changes in the knal, the changes in both AUClung and LRT0.5 
were smaller, 7 or 8 %. These may be again consistent with the fact that, for ciprofloxacin, 
the ka was kinetically a major contributor (by 62 %) in the lung exposure profile, given its 
rate-control by the sum of the ka and knal. 
 
5.3.2.4 Local lung exposure profile simulation for three molecules 
For all three molecules, ±20 % changes in the DTL produced identical ±20 % 
changes in the AUClung, while the LRT0.5 remained unchanged as this parameter is dose-
independent. For any changes in the ka and knal, the AUClung and LRT0.5 changed and the 
changes were dependent on the relative contribution of the ka and knal, as related to the 
changes in the (ka+knal). In other words, changes made to the major contributor of ka+knal 
caused greater changes in the AUClung and LRT0.5, compared to changes made to the 
minor contributor. 
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A. DTL  B. ka C. knal 
Figure 5.3-A Effects of ±20 % changes in the A) DTL, B) ka and C) knal values on the tobramycin drug mass remaining in 
the lungs vs. time profiles following inhaled administration in healthy subjects and % changes in the AUClung and LRT0.5 
values. The profiles in blue are drawn by simulation using DTL= 27.4 mg, ka= 0.45 h-1 and knal= 0.08 h-1, as derived by 
the curve-fitting of the profile data in the literature in Chapter 3. The profiles in orange and gray are drawn by simulation 
upon +20 and -20 % change in the parameter of interest. 
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A. DTL  B. ka C. knal 
Figure 5.3-B Effects of ±20 % changes in the A) DTL, B) ka and C) knal values on the calcitonin drug mass remaining in 
the lungs vs. time profiles following inhaled administration in healthy subjects and % changes in the AUClung and LRT0.5 
values. The profiles in blue are drawn by simulation using DTL= 52.9 µg, ka= 0.06 h-1 and knal= 2.32 h-1, as derived by 
the curve-fitting of the profile data in the literature in Chapter 3. The profiles in orange and gray are drawn by simulation 
upon +20 and -20 % change in the parameter of interest. 
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A. DTL  B. ka C. knal 
Figure 5.3-C Effects of ±20 % changes in the A) DTL, B) ka and C) knal values on the ciprofloxacin drug mass remaining 
in the lungs vs. time profiles following inhaled administration in healthy subjects and % changes in the AUClung and LRT0.5 
values. The profiles in blue are drawn by simulation using DTL= 16.58 mg, ka= 0.98 h-1 and knal= 0.61 h-1, as derived by 
the curve-fitting of the profile data in the literature in Chapter 3. The profiles in orange and gray are drawn by simulation 
upon +20 and -20 % change in the parameter of interest. 
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5.4      Conclusions 
In this chapter, simulation was used to study the effects of ±20 % changes in drug 
delivery (DTL) and lung disposition kinetics (ka and knal) on the systemic PK and local lung 
exposure profiles following inhaled administration. It was clear that the DTL changes 
caused identical changes in the Cmax and AUC∞ and did not affect the Tmax across all three 
drugs. In contrast, the impact of the ka and knal changes on the changes in Cmax, AUC∞ 
and Tmax appeared to depend on how each kinetic process (ka or knal) contributes to the 
overall rate of drug disposition in the lung. Similarly, the local lung exposure was a direct 
correlation with the sum of the ka and knal and thus, its impact again depended on how 
each kinetic process (ka and knal) contributes to the overall rate of drug disposition in the 
lung.  
The FDA bioequivalence criteria states that a test product is bioequivalent to a 
reference product, when the 95 % confidence interval (CI) of the test product exposure 
metrics (i.e., Cmax and AUC∞) falls within 80-125 % range of those for the reference 
product. This was with the understanding that the 80-125 % range of the Cmax and AUC∞ 
represents a ±20 % of the systemic exposure. Therefore, as a starting point, it was of 
interest to perform simulations to understand what % changes were observed in the Cmax 
and AUC∞ by introducing ±20 % changes in the DTL, ka and knal. While further simulations 
with different molecules are necessary to identify a more solid trend or classification 
regarding changes in the kinetic metrics, these simulation strategies can be an important 
tool to allow us studying changes in the PK metrics in response to drug delivery (DTL) 
and lung disposition kinetics (ka and knal). 
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CHAPTER 6 
OVERALL CONCLUSIONS, LIMITATIONS AND FUTURE DIRECTIONS 
 
 
 
This thesis project aimed to develop the lung deposition and disposition kinetic 
model to derive and predict the kinetic descriptors of lung disposition, namely, the rate 
constants for absorption (ka) and non-absorptive loss (knal). The model incorporated the 
dose delivered to the lung (DTL) and the first-order ka and knal in the lung, along with one- 
or two-compartment kinetic model for first-order systemic disposition. Appropriate 
selection of drugs and study design allowed elimination of gastrointestinal (GI) absorption 
from this model. An exhaustive literature search found that three drugs, tobramycin, 
calcitonin and ciprofloxacin, published all necessary data sets, i.e., intravenous (IV) PK 
profiles, inhaled PK profiles without GI absorption and corresponding lung deposition data 
by -scintigraphy. 
The two approaches of curve fitting- and moment analysis-based approaches were 
developed and used to derive the ka and knal values for the three drugs delivered via dry 
powder inhalers (DPIs) and/or nebulizers (NEB). In the curve fitting approach, each 
inhaled PK profile data were fitted to the model to derive the ka and knal values, while the 
DTL was fixed, as reported by the-scintigraphy data, and the systemic PK parameters 
were derived and fixed with the IV PK profiles. All the curve fittings showed acceptable 
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“goodness-of-fit” to the profiles in the literature. The ka values for all the three hydrophilic 
drug molecules were well correlated to their molecular weight. The knal values appear to 
be well aligned with the literature reporting tissue binding, lung metabolism and 
mucociliary clearance. In the moment-based analysis, the same data sets were used. The 
MRTiv and MRTinh were calculated after IV and inhaled administration, respectively, to 
estimate the mean lung residence time (MLRT) after inhalation. With the DTL, the 
bioavailability due to lung absorption (FL) was also determined. Given FL = MLRTka = 
ka/(ka+knal), the ka and knal values were then derived, which were found to be comparable 
to those derived by the curve fitting in majority of the cases.  
The curve fitting derived ka and knal values were used to predict the systemic PK 
and local lung exposure profiles by simulation upon ±20 % changes in lung delivery (DTL) 
and lung disposition (ka and knal). The DTL changes caused identical changes in the Cmax 
and AUC∞ without changing the Tmax across all three drugs. In contrast, impacts of the ka 
and knal changes to the Cmax, AUC∞ and Tmax appeared to depend on how each process 
(ka or knal) contributes to the overall rate of drug disposition in the lung.  
 
One of the significant limitations of this thesis research is a use of mean PK profile 
data from the literature by extraction, so that original PK data variability could not be taken 
into account in the ka and knal derivation. In addition, the lung disposition model was 
minimalist, combining multiple non-absorptive clearances into one first-order kinetic 
process and disregarding possible within-lung kinetic differences. While incorporating 
detailed distinctions would be ideal to understand the lung region-dependent disposition 
kinetics, it would not derive such many parameter estimates in an accurate manner, as 
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has been obtained in this thesis research. The data availability is also a limitation. The 
inhaled PK profile data and corresponding -scintigraphic lung deposition data are 
required along with the IV PK profile data. For the moment analysis-based approach, this 
limitation may be eased, if the DTL, AUC and MRT values are reported in the literature 
despite a lack of the PK profile data points. Even so, this approach does not provide 
statistics for “goodness”, so that assessment and comparison of the derived ka and knal 
values would still remain difficult.       
 
This project has attempted to resolve the kinetic complexities by lung delivery, 
deposition and disposition to understand and identify critical factors and attributes that 
contribute to outcome measures of systemic PK and local lung exposure profiles. While 
the project has been successful with the three drug molecules of its choice, it is clear that 
the study should be extended to more molecules with different physicochemical 
properties and indications to further solidify the utility of the approaches. Particularly, 
fluticasone propionate would be of most interest, as to recent efforts of developing its 
generic inhaler products. 
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APPENDIX A 
 
METHOD OF RESIDUALS USED FOR DERIVING INITIAL PARAMETER 
ESTIMATES OF IV PK PROFILE 
 
 
 
This Appendix will briefly describe the steps involved in estimating the initial 
estimates of model parameters after IV administration as detailed in Gibaldi & Perrier 
(1982).  
When the drug follows a one-compartment model after zero-order input and its 
elimination rate constant is first-order like in case of calcitonin, the concentration of the 
drug in central compartment as a function of time can be derived by: 
CC= k0 * (1- e-k10*t)                                                                                  Equation A.1 
             VC * k10 
where CC is the concentration of drug in the central compartment (plasma/serum drug 
concentration) at time t, k0 is the zero-order infusion rate for IV infusion during the infusion 
period; k10 is the first-order elimination rate constant from the central compartment; VC is 
the apparent volume of distribution of the central compartment. Equation A.1 was used 
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to calculate initial estimates of one-compartment model parameters k10 and VC for 
calcitonin to explain the IV PK profile after IV infusion reported in Buclin et al.  
When the drug follows a two-compartment model like in case of tobramycin and 
ciprofloxacin, the concentration in the central compartment as a function of time can be 
derived by the following biexponential equation after administration of drug intravenously 
as a bolus or at a constant rate infusion: 
CC= A*e-αt + B*e-βt                                                                                  Equation A.2 
where CC is the concentration of drug in the central compartment (plasma/serum drug 
concentration) at time t; α, β are apparent first order fast (distribution and elimination) and 
slow (elimination) disposition rate constants, respectively; and A and B are zero-time 
intercepts corresponding to α and β, respectively. 
The pharmacokinetic macro-rate constants A, α, B and β in equation A.2 can be 
derived from the biexponential central compartment drug concentration (CC) versus time 
curve by using method of residuals. (Gibaldi & Perrier 1982) Method of residuals is a PK 
technique for resolving a curve into its various exponential components. Since α is larger 
than β, by definition, the term A*e-αt will approach zero more rapidly than B*e-βt and 
equation A.2 will then reduce to equation A.3: 
CC= B*e-βt                                                                                               Equation A.3 
Equation A.3 in natural-logarithmic terms will be: 
Ln CC= Ln B – βt                                                                                    Equation A.4 
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This equation describes the terminal linear phase of the curve resulting from a plot of the 
natural-logarithm of plasma/serum drug concentration versus time. This terminal linear 
phase has a slope of -β, and when extrapolated to zero, it yields an intercept of Ln B. 
By subtracting the concentration-time values on the extrapolated line from the 
corresponding true plasma concentration-time values, a series of residual concentration 
(Cr)-time values will be obtained, which are described as in equation A.5: 
Cr= A*e-αt                                                                                               Equation A.5 
Equation A.5 in natural-logarithmic terms will be: 
Ln Cr= Ln A – αt                                                                                     Equation A.6 
Thus, a plot of the natural-logarithm of the residual concentration values versus time will 
yield a straight line with a slope of -α and a zero-time intercept of Ln A. Resolution of the 
biexponential curve thereby enables the determination of all parameters in equation A.2, 
which will in turn permit the estimation of the two-compartment model parameters k21, k10, 
and k12 by using the following equations: 
 
k21= Aβ+ Bα                                                                                           Equation A.7 
                    A+B 
k10= α* β                                                                                                 Equation A.8 
                   k21 
k12= α + β – k21 – k10                                                                              Equation A.9 
These steps to calculate two-compartment model parameters after IV 
bolus/infusion were then followed to calculate initial estimates of model parameters k10, 
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k12, k21 and VC for tobramycin and ciprofloxacin to explain the IV PK profile after IV infusion 
reported in Pleasants et al. and Brunner et al., respectively. 
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APPENDIX B 
 
ORIGINAL DATA SETS FROM CURVE FITTING APPROACH FOR TOBRAMYCIN IV 
AND INHALED PK PROFILES 
 
 
 
Table B.1 Tobramycin mean serum concentration vs. time profile data reported in 
Pleasants et al. after IV infusion. 
 
T (h) Mean serum concentration (mg/L) 
0.17 3.8267 
0.33 6.05078 
0.50 8.18939 
0.67 7.18595 
0.83 6.37492 
1.00 6.07669 
1.33 4.90413 
1.50 4.18039 
1.67 3.67043 
2 2.94884 
2.5 2.56958 
3 2.10497 
4 1.56 
6 0.811938 
8 0.448589 
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Table B.2 Macro-rate constants derived from tobramycin IV PK profile reported in 
Pleasants et al. by using method of residuals. 
 
A (mg/L) 8.76 
α (h-1) 1.65 
B (mg/L) 5.53 
β (h-1) 0.32 
 
The macro-rate constants in Table B.2 were used to calculate initial estimates of k10, 
k12, k21 and VC which are reported in Chapter 3. 
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A) 
 
// Tobramycin IV Two Compartment Model File 
IndVars: T 
DepVars: CC                                                                                     
Params: VC, k10, k12, k21 
//INPUT                                                                               
Dose=118.2 
TINF1=0.5 
RATEON1=Dose/TINF1 
TON1=0 
TOFF1=TON1+TINF1  
FLAGON1=UNIT(T-TON1)  
FLAGOFF1=UNIT(T-TOFF1)  
ARATE1=RATEON1*FLAGON1*(1-FLAGOFF1) 
MC'=ARATE1+k21*MP-(k12+k10)*MC 
MP'=k12*MC-k21*MP                              B) 
CC=MC/VC 
//Initial conditions 
T=0 
MC=0 
MP=0 
*** 
C)  
 
T (h) Predicted serum concentration (mg/L) 
0.17 3.2811 
0.33 5.9637 
0.50 8.4579 
0.67 7.3666 
0.83 6.5131 
1.00 5.7559 
1.33 4.6225 
1.50 4.1703 
1.67 3.7861 
2 3.1897 
2.5 2.5444 
3 2.0917 
4 1.4911 
6 0.82231 
8 0.46466 
 
Figure B.1 A) model file, B) Parameter file and C) Predicted profile of the Scientist® for 
curve-fitting the mean serum concentration vs. time profile of tobramycin following IV 
infusion. 
Parameter 
Name 
Value Lower 
Limit 
Upper 
Limit 
Fixed? 
VC 11.4 0 Infinity Yes 
k10 0.53 0 Infinity Yes 
k12 0.36 0 Infinity Yes 
k21 0.69 0 Infinity Yes 
 
 
95 
 
Table B.3 Goodness-of-fit statistics and statistical output for tobramycin IV PK profile 
curve fitting. 
 
Goodness-of-fit statistics Weighted Unweighted 
Sum of squared observations: 325.55 325.55 
Sum of squared deviations: 0.68872 0.68872 
Standard deviation of data: 0.25022 0.25022 
R-squared: 0.99788 0.99788 
Coefficient of determination: 0.9912 0.9912 
Correlation: 0.99585 0.99585 
Model Selection Criterion: 4.1997 4.1997 
Confidence Intervals 
Parameter Name: VC 
Estimated Value: 11.376 
Standard Deviation: 0.42058 
95% Range (Univariate): 10.45 12.302 
95% Range (Support Plane): 9.8349 12.917 
Parameter Name: k10 
Estimated Value: 0.53304 
Standard Deviation: 0.054272 
95% Range (Univariate): 0.41359 0.65249 
95% Range (Support Plane): 0.33417 0.7319 
Parameter Name: k12 
Estimated Value: 0.36143 
Standard Deviation: 0.10101 
95% Range (Univariate): 0.1391 0.58376 
95% Range (Support Plane): 0.0087132 0.73157 
Parameter Name: k21 
Estimated Value: 0.69437 
Standard Deviation: 0.35579 
95% Range (Univariate): 0.088723 1.4775 
95% Range (Support Plane): 0.60935 1.9981 
Variance-Covariance Matrix 
0.17689 
 
-0.012348 0.0029454  
-0.033879 0.0013208 0.010204 
-0.086985 0.015858 0.020584 
Correlation Matrix 
1 
 
-0.54099 1  
-0.79744 0.24093 1 
-0.5813 0.82127 0.57272 
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Table B.4-A Tobramycin mean (±SD) serum concentration vs. time profile data reported 
in Newhouse et al. after inhalation from DPI. 
 
T (h) Mean serum concentration (mg/L) SD (mg/L) 
0 0 0 
0.25 0.36923 0.134998 
0.5 0.42528 0.127047 
1 0.56703 0.182634 
1.5 0.57363 0.164767 
2 0.56044 0.15684 
3 0.53571 0.125062 
4 0.45659 0.113151 
6 0.33626 0.087345 
8 0.23077 0.06 
 
Table B.4-B Tobramycin mean (±SD) serum concentration vs. time profile data reported 
in Newhouse et al. after inhalation from NEB. 
 
T (h) Mean serum concentration (mg/L) SD (mg/L) 
0 0 0 
0.25 0.15041 0.091 
0.5 0.17851 0.08 
1 0.25893 0.103 
1.5 0.26116 0.091 
2 0.26446 0.089 
3 0.26116 0.077 
4 0.23141 0.07 
6 0.17686 0.052 
8 0.12066 0.052 
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A) 
//Tobramycin lung deposition and disposition PK model 
IndVars: T 
DepVars: CC 
Params: Dose, VC, k10, k12, k21, ka, knal 
ML'=-(ka+knal)*ML                               B) 
MC'=k21*MP-(k12+k10)*MC+ka*ML                                                            
MP'=k12*MC-k21*MP                                                                         
CC=MC/VC 
//Initial conditions 
T=0 
ML=Dose 
MC=0 
MP=0 
*** 
 
C) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B.2 A) model file, B) Parameter file and C) Predicted profile of the Scientist® for 
curve-fitting the mean serum concentration vs. time profiles of tobramycin following 
inhalation from DPI and NEB. 
 
Parameter 
Name 
Parameter 
Value 
Lower 
Limit 
Upper 
Limit 
Fixed? 
Dose 
(DPI) 
27.4 0 Infinity Yes 
Dose 
(NEB) 
15 0 Infinity Yes 
VC 11.4 0 Infinity Yes 
k10 0.53 0 Infinity Yes 
k12 0.36 0 Infinity Yes 
k21 0.69 0 Infinity Yes 
ka (DPI) 0.45 0 Infinity Yes 
knal (DPI) 0.08 0 Infinity Yes 
 
ka (NEB) 0.34 0 Infinity Yes 
knal (NEB) 0.08 0 Infinity Yes 
DPI NEB 
T (h) Predicted serum 
concentration (mg/L) 
T (h) Predicted serum  
concentration (mg/L) 
0 0 0 0 
0.25 0.22763 0.25 0.095597 
0.5 0.38466 0.5 0.16382 
1 0.55816 1 0.2446 
1.5 0.6196 1.5 0.27948 
2 0.62223 2 0.28876 
3 0.55315 3 0.27092 
4 0.4572 4 0.23507 
6 0.28769 6 0.16033 
8 0.17271 8 0.10243 
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Table B.5-A Goodness-of-fit statistics and statistical output for tobramycin DPI PK 
profile curve fitting. 
 
Goodness-of-fit statistics Weighted Unweighted 
Sum of squared observations: 1.9437 1.9437 
Sum of squared deviations: 0.033747 0.033747 
Standard deviation of data: 0.064949 0.064949 
R-squared: 0.98264 0.98264 
Coefficient of determination: 0.88728 0.88728 
Correlation: 0.96655 0.96655 
Model Selection Criterion: 1.7829 1.7829 
Confidence Intervals 
Parameter Name: ka 
Estimated Value: 0.45025 
Standard Deviation: 0.041451 
95% Range (Univariate): 0.35467 0.54584 
95% Range (Support Plane): 0.32647 0.57404 
Parameter Name: knal 
Estimated Value: 0.076506 
Standard Deviation: 0.042511 
95% Range (Univariate): 0.021525 0.17454 
95% Range (Support Plane): 0.050444 0.20346 
Variance-Covariance Matrix 
0.0017182 
 
0.00086527 0.0018072 
Correlation Matrix 
1 
 
0.49104 1 
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Table B.5-B Goodness-of-fit statistics and statistical output for tobramycin NEB PK 
profile curve fitting. 
 
Goodness-of-fit statistics Weighted Unweighted 
Sum of squared observations: 0.42727 0.42727 
Sum of squared deviations: 0.0050663 0.0050663 
Standard deviation of data: 0.025165 0.025165 
R-squared: 0.98814 0.98814 
Coefficient of determination: 0.92196 0.92196 
Correlation: 0.97592 0.97592 
Model Selection Criterion: 2.1505 2.1505 
Confidence Intervals 
Parameter Name: ka 
Estimated Value: 0.34124 
Standard Deviation: 0.024899 
95% Range (Univariate): 0.28382 0.39866 
95% Range (Support Plane): 0.26688 0.41559 
Parameter Name: knal 
Estimated Value: 0.078354 
Standard Deviation: 0.030372 
95% Range (Univariate): 0.0083153 0.14839 
95% Range (Support Plane): 0.012347 0.16905 
Variance-Covariance Matrix 
0.00061996 
 
0.00040206 0.00092247 
Correlation Matrix 
1 
 
0.53166 1 
 
 
 
 
 
 
 
 
 
 
 
100 
 
 
 
APPENDIX C 
 
ORIGINAL DATA SETS FROM CURVE FITTING APPROACH FOR CALCITONIN IV 
AND INHALED PK PROFILES 
 
 
 
Table C.1 Calcitonin mean (±SD) plasma concentration vs. time profile data reported in 
Buclin et al. after IV infusion. 
 
Time (h) Mean plasma concentration (µg/L) SD (µg/L) 
0 0 0 
0.25 0.096952 0.0199 
0.5 0.11276 0.025 
0.76 0.12175 0.02924 
1.01 0.17277 0.038 
1.51 0.0141 0.0037 
2 0.00399 0.0009 
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A) 
 
// Calcitonin IV One Compartment Model File 
IndVars: T 
DepVars: CC                                                                                     
Params: VC, k10 
//INPUT                                                                               
Dose=10 
TINF1=1 
RATEON1=Dose/TINF1 
TON1=0 
TOFF1=TON1+TINF1  
FLAGON1=UNIT(T-TON1)  
FLAGOFF1=UNIT(T-TOFF1)  
ARATE1=RATEON1*FLAGON1*(1-FLAGOFF1) 
MC'=ARATE1-k10*MC                                  
CC=MC/VC 
//Initial conditions                             B) 
T=0                                                                             
MC=0 
*** 
 
 
C)  
 
Time (h) Predicted plasma concentration (µg/L) 
0 0 
0.25 0.090789 
0.5 0.12658 
0.76 0.14069 
1.01 0.14626 
1.51 0.022731 
2 0.003533 
 
Figure C.1 A) model file, B) Parameter file and C) Predicted profile of the Scientist® for 
curve-fitting the mean plasma concentration vs. time profile of calcitonin following IV 
infusion. 
 
 
 
 
 
 
 
 
 
Parameter 
Name 
Parameter 
Value 
Lower 
Limit 
Upper 
Limit 
Fixed? 
VC 3.72 0 Infinity Yes 
k10 17.9 0 Infinity Yes 
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Table C.2 Goodness-of-fit statistics and statistical output for calcitonin IV PK profile 
curve fitting. 
 
Goodness-of-fit statistics Weighted Unweighted 
Sum of squared observations: 6.72E-08 6.72E-08 
Sum of squared deviations: 1.36E-09 1.36E-09 
Standard deviation of data: 1.65E-05 1.65E-05 
R-squared: 0.97973 0.97973 
Coefficient of determination: 0.95156 0.95156 
Correlation: 0.9758 0.9758 
Model Selection Criterion: 2.456 2.456 
Confidence Intervals 
Parameter Name: VC 
Estimated Value: 17.921 
Standard Deviation: 3.7647 
95% Range (Univariate): 8.2433 27.598 
95% Range (Support Plane): 5.114 30.728 
Parameter Name: k10 
Estimated Value: 3.7232 
Standard Deviation: 0.96678 
95% Range (Univariate): 1.238 6.2083 
95% Range (Support Plane): 0.43438 7.012 
Variance-Covariance Matrix 
1.42E+01 
 
-3.4649 0.93466 
Correlation Matrix 
1 
 
-0.95198 1 
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Table C.3-A Calcitonin mean (±SD) plasma concentration vs. time profile data reported 
in Clark et al. after inhalation from DPI. 
 
Time (h) Mean plasma concentration (µg/L) SD (µg/L) 
0 0 0 
0.08 0.02128 0.009 
0.17 0.04217 0.0086 
0.33 0.038 0.0131 
0.5 0.03611 0.0128 
1 0.02 0.0067 
2 0.00961 0.0067 
4 0 0 
6 0 0 
 
Table C.3-B Calcitonin mean (±SD) plasma concentration vs. time profile data reported 
in Clark et al. after inhalation from NEB. 
 
Time (h) Mean plasma concentration (µg/L) SD (µg/L) 
0 0 0 
0.08 0.02166 0.009 
0.17 0.03534 0.0086 
0.33 0.039 0.0131 
0.5 0.04143 0.0128 
1 0.03083 0.0067 
2 0.0106 0.0067 
4 0.0029 0.002 
6 0 0 
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A) 
//Calcitonin lung deposition and disposition PK model 
IndVars: T 
DepVars: CC 
Params: Dose, VC, k10, ka, knal             B) 
ML'=-(ka+knal)*ML 
MC'= ka*ML-k10*MC                                                                                
CC=MC/VC 
//Initial conditions 
T=0 
ML=Dose 
MC=0 
*** 
                                                       
 
C) 
DPI NEB 
Time (h) Predicted plasma 
concentration (µg/L) 
Time (h) Predicted plasma 
concentration (µg/L) 
0 0 0 0 
0.08 0.021041 0.08 0.016758 
0.17 0.035067 0.17 0.030866 
0.33 0.042564 0.33 0.042273 
0.5 0.038973 0.5 0.043841 
1 0.017993 1 0.030332 
2 0.0021036 2 0.0092892 
4 0.000019237 4 0.0007408 
6 1.6529E-07 6 0.000058635 
 
Figure C.2 A) model file, B) Parameter file and C) Predicted profile of the Scientist® for 
curve-fitting the mean plasma concentration vs. time profiles of calcitonin following 
inhalation from DPI and NEB. 
 
 
Parameter 
Name 
Parameter 
Value 
Lower 
Limit 
Upper 
Limit 
Fixed? 
Dose 
(DPI) 
52.9 0 Infinity Yes 
Dose 
(NEB) 
56.9 0 Infinity Yes 
VC 11.4 0 Infinity Yes 
k10 0.53 0 Infinity Yes 
k12 0.36 0 Infinity Yes 
k21 0.69 0 Infinity Yes 
ka (DPI) 0.06 0 Infinity Yes 
knal (DPI) 2.32 0 Infinity Yes 
     
ka (NEB) 0.05 0 Infinity Yes 
knal (NEB) 1.22 0 Infinity Yes 
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Table C.4-A Goodness-of-fit statistics and statistical output for calcitonin DPI PK profile 
curve fitting. 
 
Goodness-of-fit statistics Weighted Unweighted 
Sum of squared observations: 5.47E-09 5.47E-09 
Sum of squared deviations: 1.42E-10 1.42E-10 
Standard deviation of data: 4.50E-06 4.50E-06 
R-squared: 0.97411 0.97411 
Coefficient of determination: 0.93887 0.93887 
Correlation: 0.97487 0.97487 
Model Selection Criterion: 2.3503 2.3503 
Confidence Intervals 
Parameter Name: ka 
Estimated Value: 0.059249 
Standard Deviation: 0.0064283 
95% Range (Univariate): 0.044049 0.07445 
95% Range (Support Plane): 0.039462 0.079036 
Parameter Name: knal 
Estimated Value: 2.3214 
Standard Deviation: 0.45545 
95% Range (Univariate): 1.2444 3.3984 
95% Range (Support Plane): 0.91947 3.7233 
Variance-Covariance Matrix 
4.13E-05 
 
0.0024008 0.20743 
Correlation Matrix 
1 
 
0.82003 1 
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Table C.4-B Goodness-of-fit statistics and statistical output for calcitonin NEB PK profile 
curve fitting. 
 
Goodness-of-fit statistics Weighted Unweighted 
Sum of squared observations: 6.03E-09 6.03E-09 
Sum of squared deviations: 7.25E-11 7.25E-11 
Standard deviation of data: 3.22E-06 3.22E-06 
R-squared: 0.98799 0.98799 
Coefficient of determination: 0.96806 0.96806 
Correlation: 0.98934 0.98934 
Model Selection Criterion: 2.9994 2.9994 
Confidence Intervals 
Parameter Name: ka 
Estimated Value: 0.045027 
Standard Deviation: 0.0029126 
95% Range (Univariate): 0.03814 0.061915 
95% Range (Support Plane): 0.036062 0.053993 
Parameter Name: knal 
Estimated Value: 1.2232 
Standard Deviation: 0.1642 
95% Range (Univariate): 0.83892 1.6114 
95% Range (Support Plane): 0.71777 1.7286 
Variance-Covariance Matrix 
8.48E-06 
 
0.00036168 0.02696 
Correlation Matrix 
1 
 
0.75628 1 
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APPENDIX D 
 
ORIGINAL DATA SETS FROM CURVE FITTING APPROACH FOR CIPROFLOXACIN 
IV AND INHALED PK PROFILES 
 
 
 
Table D.1 Ciprofloxacin mean (±SE) serum concentration vs. time profile data reported 
in Brunner et al. after IV infusion. 
T (h) Mean serum concentration (mg/L) SE (mg/L) 
0.33 1.3631 0.08793 
0.67 0.7819 0.070346 
1.00 0.6240 0.035182 
1.33 0.5312 0.030769 
1.67 0.4244 0.069972 
2.00 0.3967 0.026373 
2.33 0.3643 0.021978 
2.67 0.3366 0.0206374 
3.00 0.2996 0.021978 
3.33 0.2858 0.030752 
3.67 0.2441 0.021978 
4.00 0.2257 0.026373 
4.33 0.2306 0.026356 
4.67 0.2122 0.030752 
5.00 0.1891 0.026376 
5.33 0.1800 0.021978 
5.67 0.1662 0.022356 
6.00 0.1757 0.013187 
6.33 0.1713 0.021961 
6.67 0.1622 0.017582 
7.00 0.1391 0.010769 
7.33 0.1439 0.012989 
7.67 0.1395 0.017582 
8.00 0.1536 0.026373 
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Table D.2 Macro-rate constants derived from ciprofloxacin IV PK profile reported in 
Brunner et al. by using method of residuals. 
 
A (mg/L) 1.58 
α (h-1) 2.06 
B (mg/L) 0.51 
β (h-1) 0.18 
 
The macro-rate constants in Table D.2 were used to calculate initial estimates of k10, 
k12, k21 and VC which are reported in Chapter 3. 
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A) 
 
// Ciprofloxacin IV Two Compartment Model File 
IndVars: T 
DepVars: CC                                                                                     
Params: VC, k10, k12, k21 
//INPUT                                                                   B)                                                             
Dose=200 
TINF1=0.17 
RATEON1=Dose/TINF1 
TON1=0 
TOFF1=TON1+TINF1  
FLAGON1=UNIT(T-TON1)  
FLAGOFF1=UNIT(T-TOFF1)  
ARATE1=RATEON1*FLAGON1*(1-
FLAGOFF1) 
MC'=ARATE1+k21*MP-(k12+k10)*MC 
MP'=k12*MC-k21*MP                                     
CC=MC/VC                                                              C) 
//Initial conditions 
T=0 
MC=0 
MP=0 
*** 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure D.1 A) model file, B) Parameter file and C) Predicted profile of the Scientist® for 
curve-fitting the mean serum concentration vs. time profile of ciprofloxacin following IV 
infusion. 
Parameter 
Name 
Value Lower 
Limit 
Upper 
Limit 
Fixed? 
VC 93.2 0 Infinity Yes 
k10 0.64 0 Infinity Yes 
k12 1.42 0 Infinity Yes 
k21 0.86 0 Infinity Yes 
T (h) Predicted serum concentration (mg/L) 
0.33 1.3536 
0.67 0.8231 
1.00 0.59845 
1.33 0.48998 
1.67 0.42847 
2.00 0.38949 
2.33 0.35969 
2.67 0.33381 
3.00 0.31144 
3.33 0.29096 
3.67 0.27143 
4.00 0.25379 
4.33 0.23733 
4.67 0.22149 
5.00 0.20713 
5.33 0.19371 
5.67 0.18079 
6.00 0.16907 
6.33 0.15812 
6.67 0.14757 
7.00 0.13801 
7.33 0.12906 
7.67 0.12045 
8.00 0.11265 
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Table D.3 Goodness-of-fit statistics and statistical output for ciprofloxacin IV PK profile 
curve fitting. 
 
Goodness-of-fit statistics Weighted Unweighted 
Sum of squared observations: 4.37 4.37 
Sum of squared deviations: 0.0094903 0.0094903 
Standard deviation of data: 0.021783 0.021783 
R-squared: 0.99783 0.99783 
Coefficient of determination: 0.99455 0.99455 
Correlation: 0.99729 0.99729 
Model Selection Criterion: 4.8796 4.8796 
Confidence Intervals 
Parameter Name: VC 
Estimated Value: 93.249 
Standard Deviation: 4.2449 
95% Range (Univariate): 84.395 102.1 
95% Range (Support Plane): 78.876 107.62 
Parameter Name: k10 
Estimated Value: 0.64064 
Standard Deviation: 0.036048 
95% Range (Univariate): 0.56544 0.71583 
95% Range (Support Plane): 0.51858 0.76269 
Parameter Name: k12 
Estimated Value: 1.4245 
Standard Deviation: 0.14872 
95% Range (Univariate): 1.1142 1.7347 
95% Range (Support Plane): 0.92091 1.928 
Parameter Name: k21 
Estimated Value: 0.8639 
Standard Deviation: 0.077395 
95% Range (Univariate): 0.70246 1.0253 
95% Range (Support Plane): 0.60185 1.126 
Variance-Covariance Matrix 
18.02 
 
-0.13651 0.0012995  
-0.58014 0.0044918 0.022119 
-0.19787 0.0021057 0.0086923 
Correlation Matrix 
1 
 
-0.89207 1 
 
-0.91893 0.83782 1 
-0.60226 0.75473 0.75517 
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Table D.4 Ciprofloxacin mean (±SD) plasma concentration vs. time profile data reported 
in Stass et al. after inhalation from DPI. 
 
T (h) Mean plasma concentration (mg/L) SD (mg/L) 
0 0 0 
0.5 0.04 0.0101695 
1 0.0311 0.0101695 
1.5 0.02655 0.0067796 
2 0.024859 8.47E-03 
2.5 0.022599 0.0080508 
3 0.02033 0.0076271 
4 0.017514 0.0063559 
6 0.012429 0.0029661 
8 0.00904 0.004661 
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A) 
//Ciprofloxacin lung deposition and disposition PK model 
IndVars: T 
DepVars: CC 
Params: Dose, VC, k10, k12, k21, ka, knal 
ML'=-(ka+knal)*ML                               B) 
MC'=k21*MP-(k12+k10)*MC+ka*ML                                                            
MP'=k12*MC-k21*MP                                                                         
CC=MC/VC 
//Initial conditions 
T=0 
ML=Dose 
MC=0 
MP=0 
*** 
C) 
T (h) Predicted plasma concentration (mg/L) 
0 0 
0.5 0.039072 
1 0.035802 
1.5 0.029719 
2 0.024721 
2.5 0.021133 
3 0.018492 
4 0.014705 
6 0.0097214 
8 0.0064798 
 
Figure D.2 A) model file, B) Parameter file and C) Predicted profile of the Scientist® for 
curve-fitting the mean plasma concentration-time profiles of ciprofloxacin following 
inhalation from DPI. 
 
 
Parameter 
Name 
Parameter 
Value 
Lower 
Limit 
Upper 
Limit 
Fixed? 
Dose 
(DPI) 
16.58 0 Infinity Yes 
VC 93.2 0 Infinity Yes 
k10 0.64 0 Infinity Yes 
k12 1.42 0 Infinity Yes 
k21 0.86 0 Infinity Yes 
ka  0.98 0 Infinity Yes 
knal  0.61 0 Infinity Yes 
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Table D.5 Goodness-of-fit statistics and statistical output for ciprofloxacin DPI PK profile 
curve fitting. 
 
Goodness-of-fit statistics Weighted Unweighted 
Sum of squared observations: 0.005357 0.005357 
Sum of squared deviations: 6.83E-05 6.83E-05 
Standard deviation of data: 0.0029216 0.0029216 
R-squared: 0.98725 0.98725 
Coefficient of determination: 0.94204 0.94204 
Correlation: 0.97792 0.97792 
Model Selection Criterion: 2.4481 2.4481 
Confidence Intervals 
Parameter Name: ka 
Estimated Value: 0.98005 
Standard Deviation: 0.11634 
95% Range (Univariate): 0.71178 1.2483 
95% Range (Support Plane): 0.63264 1.3275 
Parameter Name: knal 
Estimated Value: 0.61366 
Standard Deviation: 0.10884 
95% Range (Univariate): 0.36267 0.86464 
95% Range (Support Plane): 0.28863 0.93869 
Variance-Covariance Matrix 
0.013534 
 
0.0095603 0.011846 
Correlation Matrix 
1 
 
0.75503 1 
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APPENDIX E 
 
MODEL FILE FOR LOCAL LUNG EXPOSURE PROFILE SIMULATION 
 
 
 
//Local lung exposure profile/Drug mass remaining in lung vs. time profile simulation 
model file 
IndVars: T 
DepVars: ML 
Params: ka, knal 
//INPUT 
Dose=INPUT DOSE 
ML'=-(ka+knal)*ML 
//Initial condition 
T=0 
ML=Dose 
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